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Abbreviations 
ABL                      v-abl Abelson murine leukemia viral oncogene 
ALL                       acute lymphoblastic leukemia 
Array-CGH            array comparative genomic hybridization 
B-ALL                   B - cell acute lymphoblastic leukemia 
BAC                       bacterial artificial chromosome 
BCR                       breakpoint cluster region 
BM                           bone marrow 
bp                           base pairs 
CEP                        centromere probe 
CDKs                     cyclin dependent kinases 
CGH                       comparative genomic hybridization 
CLL                        chronic lymphocytic leukemia 
CML                       chronic myelogenous leukemia 
CNAs                     copy number alterations 
CNVs                      copy number variations 
COBRA-FISH        COmbined Binary Ratio labelling-FISH 
del                           deletion 
DNA                       deoxyribonucleic acid 
FISH                       fluorescence in situ hybridization 
GTG                       Giemsa banding, G-bands by trypsin using Giemsa 
HSCs                       haematopoietic stem cells 
HSCT                      hematopoietic stem cell transplantation 
IGHV                      immunoglobulin heavy chain variable 
ISCN                       international system for human cytogenetic nomenclature 
Kb                           kilobasepairs 
LSP                         locus-specific probe 
Mb                          megabasepaires 
MCB                       multicolor banding 
MCL                       mantle cell lymphoma 
m-FISH                   multicolor FISH 
M-FISH                  multiplex FISH 
MLPA                     multiplex ligation dependent probe amplification 
NCI                         National Cancer Institute 
NGS                        next generation sequencing 
NF-κB                    nuclear factor kappa-light-chain-enhancer of activated B cells 
No.                          number 
NK                          natural killer 
PAC                        P1-derived artificial chromosome 
PB                             peripheral blood 
PCR                        polymerase chain 
PCP                         partial chromosome paint 
PFS                         progression-free survival 
PNA                        purine nucleoside analogue 
RB                           retinoblastoma 
SKY                        spectral karyotyping 
SNP                         single nucleotide polymorphism   
WBCs                     white blood cells 
WHG                      whole human genome 
t                               translocation 
TGF-β                     transforming growth factor beta 
T-PLL                     T-cell prolymphocytic leukemia 
TTFT                      time to first treatment 
UPD                        uniparental disomy 
ZAP-70                   Zeta-chain-associated protein kinase 70 
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 Summary: 
Chronic lymphocytic leukemia (CLL) is the most frequent leukemia of adults in Western 
countries; also it is considered as a heterogeneous disease, as the overall survival of CLL patients 
is different according to the detected acquired genetic, especially chromosomal aberrations. 
Particularly important are the genes TP53, ATM, and BIRC3, which are associated with poor 
prognosis. Many techniques have been used for the detection of disease associated chromosomal 
abnormalities, such as banding cytogenetic (GTG-banding) or molecular cytogenetic analyses. 
However, especially GTG-banding is hampered in diagnostics of CLL due to the low mitotic index 
of the aberrant cells. Even after using a suitable mitogen such as 12-O-tetradecanoylphorbol-13-
acetate (TPA), the detection rate reaches only approximately 48%. Interphase fluorescence in situ 
hybridization (iFISH) was introduced to overcome this limitation; however this leads to 
underestimation of the complexity in chromosomal rearrangements. Multiplex ligation dependent 
probe amplification (MLPA) can be a way out here, and it was introduced recently for the 
diagnosis of CLL giving the opportunity to detect multiple chromosomal aberrations 
simultaneously. The present work aimed to analyze and detect cryptic chromosomal aberrations in 
150 CLL patients, by studying them comparatively for aberration detection rates using different 
approaches such as GTG-banding, iFISH and/or MLPA, in addition to array-based comparative 
genomic hybridization (array-CGH) in selected cases. 
Overall 163 acquired aberrations in 67 of 85 samples (~79%) were identified; iFISH was superior 
to MLPA in the cases with low percentage of aberrant cells, but on the other hand MLPA revealed 
additional chromosomal abnormalities in 22 cases. Based on that data a cost efficient scheme was 
suggested combining the different techniques for better diagnosis and characterization of cryptic 
chromosomal aberrations in CLL. Additionally an assessment of BIRC3 alterations, a gene 
recently found to play an important role in lymphatic leukemia, was performed on 117 CLL, and 
45 B-ALL cases. BIRC3 aberrations were detected in 23/117 (~20%) of CLL and 2/45 (~4%) of B-
ALL cases. Based on these results ATM deletions may, but must not always be associated with 
BIRC3 abnormalities. Thus BIRC3 screening should be considered as independent diagnostic 
parameter of CLL in future. Finally, 150 CLL patients have been tested for their status of TP53 
deletion. Obviously cases with isochromosome 17q and deletion of TP53 were associated with 
more complex karyotypic changes than such with deletion of TP53 due to other chromosomal 
changes. This suggests that i(17q) presents an adverse prognostic marker, which should be 
considered more in future CLL-diagnostics.   
Summary                                                                                                                                                                        2 
 
Zusammenfassung: 
Chronische lymphatische Leukämie (CLL) ist die am häufigsten auftretende Leukämieform des 
Erwachsenenalters in den sog. „westlichen Ländern“. Die CLL wird es als eine heterogene 
Erkrankung angesehen, da Überlebensrate und -zeit (overall survival = OS) von CLL-Patienten 
durchaus unterschiedlich ist. Die OS hängt stark von den vorliegenden und entsprechend erfassten, 
erworbenen genetischen, insbesondere Chromosomenveränderungen ab. Von besonderer 
Bedeutung sind hierbei die Gene TP53, ATM und BIRC3, die allgemein mit einer schlechten 
Prognose der Krankheit assoziiert werden. Eine Vielzahl an Techniken wurden und werden zum 
Nachweis von CLL-assoziierten Chromosomenanomalien eingesetzt wie Bänderungs-Zytogenetik 
(GTG-Färbung) oder molekulare Zytogenetik. Hierbei ist anzumerken, dass insbesondere eine 
Karyotypanalyse durch den niedrigen mitotischen Index der aberranten CLL-Zellen nur 
eingeschränkt möglich ist. Dies gilt auch dann noch, nachdem geeignete Mitogene angewendet 
wurden, wie 12-O-Tetradecanoylphorbol-13-Acetate (TPA); hier sind Mitosen in nur etwa 48% 
der Fälle zu erwarten. Um solche Einschränkungen der Analyse zu umgehen wurde die Interphase 
Fluoreszenz in situ Hybridisierung (iFISH) eingeführt; jedoch kann der Einsatz dieser Methode zu 
einer Unterschätzung der vorliegenden Komplexität an Chromosomenaberrationen führen. Hier ist 
die Multiplex ligation dependent probe amplification (MLPA) als weiterer Fortschritt in der CLL-
Diagnostik anzuführen, da diese Methode die Möglichkeit eröffnet gleichzeitig viele / viel mehr 
Chromosomenaberrationen zu erkennen. Die vorliegende Arbeit wurde mit dem Ziel durchgeführt 
zuvor kryptische chromosomale Aberrationen in 150 CLL Fällen nachzuweisen, und zwar durch 
den vergleichenden Einsatz von GTG-Bänderung, iFISH und MLPA, sowie in einzelnen Fällen 
ergänzt durch Mikro-array-Analyse (array-CGH). Insgesamt wurden 163 erworbene Aberrationen 
in 67 von 85 Fällen (~ 79%) nachgewiesen; iFISH hatte in solchen Fällen bessere Nachweisraten 
als die MLPA, welche nur einen geringen Anteil an anomalen Zellen hatten; im Gegensatz hierzu 
konnte die MLPA-Technik zusätzliche nicht mittels FISH erfassbare Chromosomenanomalien in 
22/85 Fälle erfassen. Auf diesen Ergebnissen beruhend konnte hier ein kosteneffizientes 
Analyseschema entwickelt werden bei dem GTG-Bänderung, MLPA und iFISH so kombiniert, 
abgestimmt und gezielt eingesetzt werden, dass eine optimale Charakterisierung von kryptischen 
Chromosomenaberrationen bei CLL-Patienten möglich wird. Weiterhin wurden 117 CLL und 45 
B-ALL Fälle auf das Vorliegen von BIRC3 Veränderungen untersucht. Letztere wurden in 23/117 
(~ 20%) der CLL und 2/45 (~ 4%) der B-ALL-Fälle nachgewiesen. Hieraus, und aus der 
gleichzeitigen Feststellung des ATM-Deletionsstatus der entsprechenden Patienten konnte erstmals 
gezeigt werden, dass ATM Deletionen zusammen mit BIRC3 Genveränderung vorkommen 
können, aber nicht müssen. Ein Screening auf BIRC3 für eine verbesserte Diagnosestellung bei der 
CLL wird vorgeschlagen. Abschließend wurden 150 CLL-Patienten auf ihren Isochromosom-17q-
Status hin getestet. Offensichtlich waren Fälle mit Isochromosom-17q und Deletion von TP53 mit 
komplexeren karyotypischen Veränderungen assoziiert als solche Fälle in denen Deletion von 
TP53 aufgrund anderer chromosomaler Veränderungen vorlag. Das deutet darauf hin, dass 
Isochromosom-17q einen negativen prognostischen Marker darstellt, der künftig mehr Beachtung 
bei der CLL-Diagnostik finden sollte. 
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1. Introduction 
1.1. Cytogenetic and molecular (cyto)genetics 
The beginning of diagnostic cytogenetics arose in the mid of 19th century. Then the normal 
number of chromosomes in the human somatic cell was finally accurately identified in 1956 by 
Tjio and Levan (Tjio and Levan 1956), which was independently confirmed in the same year by 
Ford and Hamerton (Ford and Hamerton 1956). 
The continued technical improvements in the cytogenetic field enabled the researchers to identify 
chromosomal abnormalities, which are correlated with specific disorders, such as, in 1959 
Lejeune and colleagues found the trisomy for chromosome 21 in fibroblast cultures from patients 
with Down syndrome (Lejeune et al. 1959). 
In 1960, Peter Nowell and David Hungerford identified a minute chromosome in the white blood 
cells (WBCs) of patients with chronic myelogenous leukemia (CML), which was called 
Philadelphia chromosome (Nowell and Hungerford 1960). 
Thirteen years later, it was discovered that, this chromosome is a product of balanced 
translocation between the long arms of chromosomes 9 and chromosome 22; specifically a 
t(9;22)(q34;q11) (Rowley 1973). 
The development of chromosome preparations and banding techniques in the end of the 1960s 
allowed the more precise identification and characterization of inherited and acquired alterations 
in human malignancies (Caspersson et al. 1968). 
RB1 (retinoblastoma) gene, which is located in 13q14, was the first identified tumor suppressor 
gene. As in 1983 Cavenee et al. introduced the proof of Knudson s´ "two-hit" hypothesis. They 
reported that cancer may originate from the (functional) loss of both alleles of the RB1 gene, 
when a germline mutation is present on one allele and a subsequent mutation of the other allele 
takes place (Cavenee et al.1983, Knudson et al. 1971). 
 
1.1.1. Chromosome banding 
The development of banding and staining protocols between 1968 and 1980s facilitated the 
identification of many recurrent numerical and structural chromosomal abnormalities. Also 
chromosome analysis has been used widely in diagnosis of leukemia and lymphoma (Lawler 
1977). 
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Giemsa (G-) banding was introduced after the development of Q-banding. Giemsa stain is used 
in G-banding after proteolytic enzyme treatment of the chromosome preparations. This type of 
staining produced highly reproducible dark and light bands along each chromosome, which 
could be seen by standard light microscopy. G-banding technique is still considered as gold 
standard for the detection of both numerical (gain or loss of a chromosome) and structural 
aberrations (e.g. translocation, deletion, inversion, fragile sites, etc.), as it provides a whole-
genome perspective. In spite of that the resolution of G-banding is limited (approximately 400-
550 bands per haploid tumor cytogenetic genome), thus chromosomal aberrations can be missed 
and complex aberrations are too difficult to be resolved even by skilled cytogeneticists (Wang 
and Fedoroff 1972, Yunis 1976, Othman et al. 2014). 
Based on the banding patterns for each chromosome a system of nomenclature was introduced, 
and this international system for human cytogenetic nomenclature (ISCN) is still in place and 
actualized regularly (Shaffer et al. 2013). 
 
1.1.2. Molecular cytogenetics 
Molecular cytogenetics involves the combination of both molecular and cellular levels in 
microscopic analyses (Speicher and Carter 2005). The identification of particular chromosomal 
rearrangements such as too small or too complex aberrations could be achieved through the 
application of more sensitive and sophisticated techniques than G-banding (Li and Pinkel 2006). 
Thus, fluorescence in situ hybridization (FISH) has been introduced as a suitable method for the 
characterization of both constitutional and acquired chromosomal abnormalities by application of 
chromosome-specific probes and probe sets (Pinkel et al. 1986). 
For further identification of new biomarkers and potential therapeutic targets in leukemia and/or 
cancer, other techniques were developed such as comparative genomic hybridization (CGH), 
array-based CGH (array-CGH) and single nucleotide polymorphism (SNP array-CGH), and 
multiplex ligation dependent probe amplification (MLPA) (Glassman and Hayes 2005, Le 
Scouarnec and Gribble 2012, Hömig-Hölzel and Savola 2012). 
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1.1.2.2. Probes used for FISH 
The accuracy and reliability of FISH analysis depend particularly on the specificity and 
sensitivity of the applied probes and the hybridization detection efficiency (Divane et al. 1994). 
There are many different types of DNA probes that can be used in FISH, which have been 
grouped as outlined below. 
 
1.1.2.2.1. Locus-specific probes (LSP) 
LSP bind to a particular region of a chromosome or locus of 0.1 to several megabase pairs (Mb) 
in size. 
They can detect amplified oncogenes, deletion of tumor suppressor genes, fusion and/or 
translocations of genetic regions involved in cancer; they are applied in (leukemia) diagnostics 
and research (Liehr et al. 2015). 
 
1.1.2.2.2. Chromosome painting probes 
Whole chromosome painting (WCP) probes, which are generated by flow sorting or whole 
chromosome microdissection, hybridize the entire length of the chromosome. In addition to that 
partial chromosome painting (PCP) probes, which are generateable only by microdissection, 
could be used to label the short and long arm of a particular chromosome or chromosomal 
subregions. PCPs and WCPs are particularly useful for examining both structural and numerical 
chromosomal abnormalities in leukemia (Cremer et al. 1988, Pinkel et al. 1988, Guan et al. 
1994). 
 
1.1.2.2.3. Centromeric probes 
Chromosome-specific centromeric probes (CEP) are generated from repetitive sequences found 
in the centromeric regions of the human chromosomes, and commercially available CEP probes 
are used to determine whether an individual has the correct number of chromosomes in both 
interphase and metaphase, such as in Down syndrome cases (Liehr et al. 2015). 
 
1.1.2.2.4. Multicolor FISH probe (mFISH) 
Multicolor FISH (mFISH) has been reported for the first time in 1989 by Nederlof and 
coworkers (Nederlof et al. 1989). Several approaches have been developed, that permit the 
simultaneous painting of all 24 human chromosomes in specific color combinations: spectral 
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karyotyping (SKY) (Schröck et al. 1996), multiplex FISH (M-FISH) (Speicher et al. 1996), m-
FISH (Senger et al. 1998), COmbined Binary Ratio labelling-FISH (COBRA-FISH) (Tanke et al. 
1999) and 24-color-FISH (Azofeifa et al. 2000). In all of these techniques a series of four to 
seven different fluorochromes in a combinatorial labeling and/or ratio-labeling is used (Riegel 
2014, Liehr et al. 2004, Liehr 2009). Nowadays, SKY and M-FISH are the most commonly 
applied WCP-based FISH approaches. Each of these techniques provides a precisely tool for 
characterization of complex chromosomal abnormalities in a single hybridization, and in one 
metaphase spread (Liehr 2015). 
 
1.1.2.2.5. FISH-banding approaches 
Although multiple FISH-banding approaches were reported, the only routinely used one is 
multicolor chromosome banding (MCB). It is available as a chromosome-specific and a whole 
genomic variant; the latter is called multitude multicolor banding (mMCB). MCB and mMCB is 
widely applied to describe marker and/or derivative chromosomes in clinical and tumor 
cytogenetics (Weise et al. 2003, Liehr et al. 2002a, 2002b, Liehr 2009). 
 
1.1.2.3. Array comparative genomic hybridization (array-CGH) 
Comparative genomic hybridization (CGH) has been introduced in 1992 for the comprehensive 
analysis of the entire genome and characterization of genetic imbalances in tumors, which could 
not be karyotyped (Kallioniemi et al. 1992). 
Subsequently array-based CGH (array-CGH) technique was established, which has much higher 
resolution than CGH [i.e. ~50-100 kilobases (kb)]. In this approach large numbers of mapped 
genomic clones, initially BAC or PAC (bacterial/P1-derived artificial chromosomes), which are 
spotted onto a standard glass slide (Fig.1.2) have been used as hybridization targets instead of the 
metaphase chromosomes (Solinas-Toldo et al. 1997, Pinkel et al. 1998). 
Array-CGH is suited to identify chromosomal imbalances particularly in leukemia and 
lymphoma, but balanced aberrations such as recurrent balanced translocations, inversions or 
insertions cannot be detected by this approach (Riegel 2014, Le Scouarnec and Gribble 2012).  
In contrast with array-CGH, SNP-array-CGH based approaches have the additional advantage of 
detecting copy number neutral loss of heterozygosity, which may be hints on deletions or 
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During the past decade, there has been tremendous progress in molecular genetics approaches 
(Murphy and Bustin 2009, Kohlmann et al. 2013). 
In the following emphases is given only to a few selected developments that are of special 
interest for this work. 
 
1.1.3.1. Multiplex ligation-dependant probe amplification (MLPA) 
MLPA is one of the variations of polymerase chain (PCR) reaction based techniques.  
MLPA can detect simultaneously the copy number changes, DNA methylation, and point 
mutations of up to 50 genomic DNA sequences in one single experiment (Fig 1.3), as it depends 
on specifically bound probes which are amplified by universal primers.  
MLPA was first described for the detection of exon alterations in the human BRCA1, MSH2 and 
MLH1 genes, and the detection of trisomies such as present in Down syndrome (Hömig-Hölzel 
and Savola 2012, Schouten et al. 2002). 
Lately, MLPA has been applied in both molecular diagnosis of tumors and in cancer research 
such as glioma, uveal melanoma, acute lymphoblastic leukemia (ALL), and breast cancer 
(Hömig-Hölzel and Savola 2012).  
Despite the advantages of MLPA as a fast, reliable, cost-effective technique, and e.g. method of 
choice for routine diagnostic of chronic lymphocytic leukemia (CLL), there are many limitations 
connected with this technique. MLPA is not suitable for the detection of balanced translocations, 
inversions, and unknown point mutations. Also in tumor cases which have low percentage of 
aberrant cells alterations may be missed by MLPA. Still in these situations sensitivity of MLPA 
could be increased by multiple target probes for the same chromosomal region or gene. 
Heterozygous deletions and/or duplications can be detected reliably by MLPA only if the sample 
contains at least 20% to 30% of the tumor cells in the case of deletion, and 40% of aberrant cells 
in duplication (Hömig-Hölzel and Savola 2012, Alhourani et al. 2014). 
In spite of the limitation of MLPA technique, it is a powerful tool for diagnosis and progression 
of cancer, considering all possible shortcuts adequately (Hömig-Hölzel and Savola 2012). 
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1.2. The biology of leukemia 
The emergence of blood cells is a complex and precise process, which is controlled by a number 
of humeral and cellular factors. It takes place primarily in the bone marrow, where all cellular 
blood components are derived from a pool of self-renewing haematopoietic stem cell (HSC) 
resides, which have the ability to differentiate into two main lineages: myeloid and lymphoid 
stem cells (Longo 2013). 
Subsequently lymphoid progenitors can differentiate into B- , T-, or natural killer (NK) cell lines. 
The differentiation of B-lymphocytes (or B-cells) occurs in the bone marrow, whereas T-
lymphocytes (or T-cells) progenitors migrate to the thymus. In Thymus they undergo several 
steps of proliferation and differentiation, and after that mature B- and T-cells migrate to 
peripheral lymphoid organs through the bloodstream (Hardy and Hayakawa 2001, Rothenberg et 
al. 2008). 
The development of myeloid progenitors leads to the production of granulocytes, monocytes, 
erythrocytes, or platelets, which have different roles in the innate immunity, the adaptive 
immunity, and blood clotting (Kondo et al.2010). 
The mechanisms which are involved in normal blood cells proliferation and differentiation are 
regulated very strictly; many factors have been identified in this process such as growth factors, 
interleukins, and transforming growth factor beta (TGF-β). The alterations in these regulation 
mechanisms can lead to uncontrolled cell proliferation and/ or failure in differentiation of 
progenitor cells to mature cells (Hardy and Hayakawa 2001). 
Leukemia is a neoplastic proliferation of hematopoietic stem cells. It is classified according to 
the length of survival of the patients and the predominant cell lineage which is represented by the 
leukemic clone into four broad subtypes: acute lymphoblastic, acute myelogenous, chronic 
lymphocytic, and chronic myelogenous (Davis et al. 2014) 
Whereas acute lymphoblastic leukemia appears more frequently in children, the other subtypes 
occur more often in adults. In addition to that acute leukemia is characterized by a rapid increase 
in the number of immature lymphoid or myeloid precursors in the bone marrow and the 
peripheral blood, i.e. immediate treatment is required (Mullighan et al. 2013, Dighiero et al. 
2008). The development of chronic leukemia tends to be slower than acute leukemia, as the 
malignant cells in chronic forms are capable of relatively maturation despite the uncontrolled 
proliferating (Rodríguez-Vicente et al. 2013). 
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1.3. Chronic lymphoblastic leukemia (CLL) 
Chronic lymphocytic leukemia (CLL) is the most frequent hematological malignancy in adults in 
Western countries, and it appears mainly in individuals >50 years of age (Chiorazzi et al. 2005). 
CLL is characterized by the accumulation of small B lymphocytes with a mature appearance in 
blood, bone marrow or other lymphoid tissues. Also it is considered as a heterogeneous disease, 
as the CLL patients show different and distinct clinical course and response to treatment 
according to the detected cell morphology, immunophenotype, as well as cytogenetic molecular 
genetic characteristics (Dighiero et al. 2008, Rodríguez-Vicente et al. 2013). 
Whereas approximately one-third of CLL patients survive for long time without requirement of 
treatment and have no or minimal signs and symptoms during their entire disease course, others 
can develop an aggressive clinical outcome of the disease including enlarged lymph nodes, 
enlarged spleen, and severe immunoglobulin deficiencies. The diagnosis of CLL is, according to 
the National Cancer Institute (NCI) guidelines, based on a clonal expansion of at least 5,000 B 
lymphocytes per μl in the peripheral blood for the duration of at least 3 months, and a 
characteristic immunophenotype combining the presence of CD19, the T-cell antigen CD5, and 
CD23 (Dighiero et al 2000, Matutes et al. 1994, Cheson BD et al. 1996). 
For the classification of CLL two staging systems are used: The Rai system which is applied 
more often in the United States, beside the Binet staging system which is the more prevailed in 
Europe. Both systems are suited for the assessment of disease progression and treatment 
planning, but they are not very effective for predicting early disease progression (Döhner et al. 
2000, Zwiebel et al. 1998). 
Along with the stage, additional prognostic markers are available to predict a patient's chances, 
in particular at early stages. The adverse prognostic factors such as advanced age, male gender, 
not-mutated IGHV (immunoglobulin heavy chain variable) gene, and high proportion of CLL 
cells containing ZAP-70 (more than 20%) or CD38 (more than 30%) are associated with shorter 
survival time. Favorable prognostic factors are low proportion of CLL cells containing ZAP-70 
(20% or less) or CD38 (30% or less) and CLL cells with a mutated IGHV (Cramer et al. 2011, 
Rodríguez-Vicente et al. 2013). 
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1.3.1. Cytogenetic abnormalities in CLL 
CLL is characterized by a high diversity in chromosomal aberrations. Several studies showed 
that detection and exact characterization of these abnormalities is essential in CLL prognosis and 
treatment. The International Workshop on Chronic Lymphocytic Leukemia guidelines consider 
the assessment of chromosomal abnormalities by FISH mandatory in clinical trials and desirable 
in general practice as a pre-treatment evaluation (Hallek et al. 2008). In the following the most 
important good, intermediate and adverse prognostic (cyto)genetic markers in CLL are 
presented. 
 
1.3.1.1. 13q14 Deletion 
Deletion within the 13q14 region is the most frequent aberration in CLL, with a prevalence of 
40-60%, and it is associated with good prognosis; such CLL patients are also denominated being 
of “13q-“type. But during the last years, several studies indicated that the situation may be more 
complex, suggesting that the percentage of cells with deletion, as well as the size of the deletion 
itself could influence the prognosis. Deletion in this region can vary substantially in size, ranging 
from only 300 kbp up to >70 Mbp. Thereby, other (tumor suppressor) genes located in 13q14.2 
(RB1 gene) or 13q14.3 as microRNAs (miR-15a and miR16-1) and DLEU7 gene can be deleted 
as well (Döhner et al. 2000, Dal Bo et al. 2011). 
Thus, two types of 13q14 deletions are proposed: del(13q) type I (short), which includes only 
13q14.3; and del(13q) type II (larger), which includes the RB1 locus with significantly shorter 
time to first treatment (TTFT) and overall survival (OS). Also the CLL patients who are carrying 
a high percentage (≥70 %) of 13q- cells have a shorter overall survival (OS) than patients with 
<70% 13q- cells, as well as a shorter TTFT (Dal Bo et al. 2011). 
In contrast to other recurrent abnormalities in CLL, 13q14 deletions could be heterozygous 
(monoallelic) or homozygous (biallelic). Biallelic losses in 13q14 are characteristically small and 
do not involve RB1. Also biallelic loss has been described in nearly 24% of 13q-type CLL 
patients (Garg et al. 2012). 
Several studies suggested that 13q14 heterozygous deletion is an early event in CLL, whereas 
deletion of the second copy of this region occurs at a later stage. Nevertheless the clinical impact 
of the presence of biallelic losses in 13q has been discussed controversially. Some authors 
hypothesized that the biallelic status is associated with a more aggressive clinical course as it 
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results from a karyotypic evolution, while others suggested that homozygosity does not affect 
TTFT or OS (Chena et al. 2008, Van Dyke, et al. 2009, Garg et al. 2011, Puiggros et al 2013). 
Still it is noteworthy that CLL patients with a monoallelic del(13q) show lower lymphocyte 
growth kinetics than patients with biallelic deletions (Rodriguez-Vicente et al. 2013). 
 
1.3.1.2. Trisomy 12 
Trisomy 12 is the third most common chromosomal abnormality in CLL, occurring in 10-20% of 
cases. It can be associated with other chromosomal rearrangements such as trisomy of 
chromosomes 18 and 19, as well as IGH rearrangement (Rodriguez-Vicente et al. 2013). 
Trisomy 12 is associated with an intermediate prognosis and an atypical morphology or 
immunophenotype. Nevertheless, this category still is controversial, as recent analysis of 
prospective trials suggested that although progression-free survival (PFS) may be shorter in CLL 
patients with trisomy 12, the overall survival is favorable. In concordance with this, trisomy 12 
in CLL is only rarely accompanied by TP53 mutations, but it is highly associated with mutated 
NOTCH1, as well as CD38 expression. The latter which could explain to some extent the bad 
prognosis of these subgroups of patients, and thus the different survival rates for this trisomy 12 
patients (Hallek et al. 2010, Matutes et al. 1996). 
Although trisomy 12 appears early in CLL evolution and thus could be a trigger for secondary 
chromosomal aberrations or mutations such as NOTCH1 and FBXW7, until now the critical 
genes which are involved in formation of this aberration remain unknown (Puiggros et al. 2014). 
 
1.3.1.3. 11q23 deletion 
Deletions in 11q23 are detected in 5 to 20% of CLL patients, and they appear generally in 
younger patients. Also they are associated with a more rapid progression of the disease and a 
shorter overall survival (Marasca et al 2013, Puiggros et al. 2014). 
11q23 deletions are highly variable in size, therefore these CLL-cases can be classified according 
to the size into “classical or large deletion” (more common and the deletion is normally >20 
Mbp) and “atypical or small deletion” (uncommon and more frequently associated with ATM 
mutations) (Gunn et al. 2009). 
The minimal affected region includes the chromosomal bands 11q22.3-q23.1, which harbor the 
ATM gene in almost all cases, as well as other genes such as BIRC3 (Puiggros et al. 2014). 
1.Introduction                                                                                                                                                               15 
ATM gene activates cell cycle checkpoints, and it has a central role in the DNA damage pathway 
as it can induce apoptosis in response to DNA breaks. ATM mutations have been reported in only 
8–30% of patients with del (11q), which indicates that other genes could contribute in the 
pathobiology of 11q deletions in CLL. One of these genes is BIRC3, which is located ~6Mb 
centromeric to the ATM gene locus, at 11q22 and it is considered to be a negative regulator of the 
MAP3K14 serin-treonine kinase, which is the central activator of non-canonical NF-κB signaling 
pathway (Rossi et al 2014, Rodriguez-Vicente et al. 2013). 
BIRC3 disruption, mutations and/or deletions are rarely detected in CLL at diagnosis (4% of 
patients). However BIRC3 involvement has been reported in 24% of fludarabine-refractory CLL 
patients. Thus BIRC3 disruption has been suggested to be specifically associated with a chemo-
refractory CLL subtype (Rossi et al. 2014). 
 
1.3.1.4. 17p13 deletion 
While deletions in 17p have been reported in 3-8% of CLL patients at diagnosis, the detection 
rate of this chromosomal abnormality increases up to 30% in CLL patients with advanced and/or 
relapsed disease. Thus, it is one of the most frequently acquired aberrations triggered after 
treatment, and most cases with del (17p) show loss of one copy and mutation of the remaining 
copy of TP53 gene (Delgado et al. 2012, Döhner et al 1995). 
17p-deletion is usually associated with a very aggressive clinical course and the shortest overall 
survival besides lack of response to therapy. Nonetheless, the percentage of aberrant cells has a 
clinical relevance, as the cut-off value for the percentage of 17p-deleted nuclei that predicted 
adverse outcome has been identified to be 20% (Puiggros et al. 2014, Greipp et al. 2013). 
The critical tumor suppressor gene in this region is TP53. This gene plays an essential role in 
inducing apoptosis or cell cycle arrest after DNA damage so that the patients harboring 17p 
deletion and/or TP53 mutations do not respond to standard initial therapy (fludarabine and 
alkylating agents), because the mechanism of these drugs is TP53-dependent. However, 
fludarabine refractoriness is caused by TP53 disruption in approximately 40% of CLL patients 
who did not respond to treatment, i.e. here other treatment approaches should be considered 
(Zenz et al. 2009, Rodriguez-Vicente et al. 2013). 17p-deletion often encompasses most of 
chromosome 17 short arm, and also it can be associated with the formation of an isochromosome 
i(17q) (Scheurlen et al. 1999). 
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Generally the formation of isochromosomes can occur during mitosis and meiosis, either by a 
misdivision of the centromere or by chromatid exchange involving two homologous 
chromosomes. Recently i(17q) in CLL has been reported to be associated with more complex 
karyotype, which could be a hint for more aggressive course of the disease than deletion of TP53 
alone (Mertens et al. 1994, Thompson et al. 2015, Alhourani et al. in press). 
 
1.3.1.5. 14q32.33 rearrangements  
CLL-associated chromosomal rearrangements in 14q32.33 could be either deletions (in 12-15% 
and includes IGH locus) being associated with a good prognosis, or translocations which were 
initially associated with a poor prognosis. Overall, recurrent balanced translocations involving 
14q32.33 are rare in CLL.  
However, the chromosomal partners involved have influence on the prognosis. While 
translocation t(14;19)(q32;q13) (IGH/BCL3) involving, trisomy 12, complex cytogenetics and 
unmutated IGHV has an inferior prognosis, the translocation t(14;18)(q32;q21) (IGH/BCL2) is 
not accompanied with complex karyotype or aggressive course of disease.  
On the contrary, translocations involving IGH and MYC gene in 8q24.2, identify a subgroup of 
CLL with higher incidence of poor prognostic features (Quintero-Rivera et al. 2009, Cavazzini et 
al.2008, Mayr et al 2006, Huh et al. 2008). 
 
1.3.1.6. Other abnormalities 
Several other recurrent chromosomal abnormalities have been described in CLL, such as deletion 
of the long arm of chromosome 6 which appears in approximately 6% of CLL patients and is 
associated with intermediate prognosis, atypical morphology, splenomegaly, and higher 
detectable rates of CD38. Also Schwaenen et al. (2004) described 2p gains, including MYCN 
gene in a low proportion of CLL cases. Also abnormalities like 8p losses and 8q gains, total or 
partial trisomy 3, trisomy 8 and /or trisomy 18 have been reported in CLL (Cuneo et al. 2004, 
Fabris et al. 2013, Puiggros et al. 2014, Rodriguez-Vicente et al. 2013, Stilgenbauer et al. 1999, 
Schwaenen et al. 2004). 
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1.3.1.7. Complex karyotype 
The presence of three or more chromosomal aberrations per patient is considered as a complex 
karyotype. The incidence of complex karyotypes in CLL is 20% (Puiggros et al. 2014). 
The genomic complexity is associated with progressive and aggressive disease, short survival, 
and decreased therapeutic efficacy. Also there is highly significant association between complex 
karyotypes and 11q or 17p deletions. Ouillette et al. (2010) demonstrated, that genomic 
complexity in CLL was a consequence of an impaired DNA double-strand break response due to 
multiple gene defects, including not only TP53, but also ATM and other genes located in 11q or 
RB1 gene located in 13q14 (Kujawski et al.2008, Ouillette et al. 2010). 
 
1.3.1.8. Somatic mutations in CLL.  
The mutational status of immunoglobulin heavy chain variable (IGHV) gene in CLL has a strong 
and independent prognostic value. Accordingly CLL patients with unmutated IGHV genes have 
higher risks of relapse after stem cell transplantation and they reveal more frequently poor 
prognosis aberrations (11q-, 17p-); in addition to that they have shorter OS. Favorable 
aberrations (13q as a single abnormality) are more frequent in such CLL patients with mutated 
IGHV gene who have better OS (Oscier et al. 2002, Hamblin et al. 1999, Ritgen et al. 2003). 
The IGHV mutation status is strongly associated with ZAP-70 expression levels: CLL patients 
with mutated IGHV genes are ZAP-70-positive, whereas ZAP-70-negative ones present more 
frequently the unmutated IGHV status. Thus, the ZAP-70 expression levels have been suggested 
as a surrogate marker for the investigation of IGHV mutation status (Wiestner et al. 2003, 
Orchard et al. 2004). 
Also, next-generation sequencing (NGS) techniques provided better insights into genomic 
complexity and heterogeneity of CLL. Novel gene mutations have been identified in CLL, such 
as in NOTCH1 and SF3B1. The detection rate of such abnormalities is 5% to 20%, and they are 
associated with advanced disease and poor prognosis (Quesada et al. 2012, Rodriguez-Vicente et 
al. 2013). 
NOTCH1 encodes a transmembrane protein that acts as a ligand-activated transcription factor. 
NOTCH1 signaling plays a critical role in CLL cell survival and apoptosis resistance. The 
mutation of NOTCH1 leads to oncogenic pathway activation and it is more frequently associated 
with trisomy 12, unmutated IGHV, and poor prognosis. In addition to that the presence of 
1.Introduction                                                                                                                                                               18 
NOTCH1 mutation is considered as an independent predictor of shorter overall survival in CLL 
(Balatti et al. 2012, Campregher et al. 2014). 
Finally, SF3B1 gene is to mention as a core component of the spliceosome, which is involved in 
the splicing of precursor messenger RNA and in the formation of mature mRNA. Mutations in 
this gene appear in ~10% of CLL patients at diagnosis, and are associated with poor prognosis 
markers such as del (11q) and unmutated IGHV status. Interestingly, recurrent mutations of 
SF3B1 have been reported in 17% of CLL patients who showed refractory to fludarabine 
treatment (Rossi et al. 2011, Quesada et al. 2012). 
 
1.3.2. Treatment of CLL 
Many factors play a role in the determination of the treatment of CLL such as the prognosis 
based on afore mentioned markers, patients’  age, and the ability of the patient to tolerate side 
effects of treatments (Smolewski et al. 2013). The main used treatments are: 
 
1.3.2.1. Standard chemotherapy and immunochemotherapy 
Chemotherapy is recommended only for the CLL patients with advanced or progressive disease, 
as some CLL patients show a stable clinical course of the disease and they could survive for 
many years without any treatment (Dighiero et al. 2000). 
Previously, chlorambucil was the drug of choice for the treatment of CLL patients with 
progressive or advanced disease. Currently, purine-nucleoside-analogue- (PNA-) based regimens 
such as fludarabine are considered the first line treatment for CLL. They could be used as a 
monotherapy or in a combination with cyclophosphamide, as the combination therapy appeared 
to be more effective than monotherapy with respect to overall response, and complete remission 
(Dighiero et al. 1998, Rai et al. 2000, Eichhorst et al. 2006). Addition of monoclonal antibodies 
such as rituximab to the combination of fludarabine and cyclophosphamide can increase the 
overall survival and complete remission of the CLL patients, and it is proved to be especially 
effective in refractory/relapsed CLL patients to the dual treatment (Hallek et al. 2010, Robak et 
al. 2010). 
Rituximab is considered as anti-CD20, which is primarily found on the surface of B cells, 
therefore rituximab is used to treat diseases which are characterized by over-proliferation of B 
cells. Whereas this combination of drugs is acceptable for younger, physically fit patients, it has 
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limitations in the less fit group, mainly due to the risk of myelosuppression (Smolewski et al. 
2013). 
Recent clinical trial suggested bendamustine, which is a bifunctional agent composed of an 
alkylating nitrogen mustard group and a purine-like benzimidazole ring to be included in CLL 
treatment regimens (Knauf et al. 2009). On the other hand, alemtuzumab, which is a 
recombinant, humanized anti-CD52 monoclonal antibody, is recommended as a first line 
treatment in the CLL patients with 17p deletion and as a second- or third line treatment alone or 
in combination with other antineoplastic drugs in the CLL patients without 17p deletion, 
especially for those with hyperleukocytosis and no bulky nodal disease (Badoux et al. 2011, 
Hillmen et al. 2007, Gritti et al. 2012) 
 
1.3.2.2. Stem cell transplantation 
Although allogeneic hematopoietic stem cell transplantation (allo HSCT) introduces the only 
potentially curative treatment option for CLL patients, this approach is suitable for only a 
minority of CLL patients, because fully ablative regimens are associated with significant 
morbidity and mortality. Thus it has been considered as the treatment of choice for physically fit 
CLL patients who carry poor-risk features, such as refractory to purine analogs, short response 
time (<24 months) to intensive treatments, and/or presence of 17p/TP53 abnormalities 
(Jaglowski et al. 2012). Recently, reduced-intensity conditioning was introduced for allo HSCT 
(mini allo HSCT), which is better tolerated than the myeloablative one (Smolewski et al. 2013). 
 
1.3.2.3. New anticancer agents in CLL 
A number of novel therapies and antibodies are available now for the treatment of CLL, such as 
Obinutuzumab (GA101) which is the first humanized anti-CD20 monoclonal antibody. It has 
been reported in preclinical studies to be more effective than rituximab in depleting B cells, 
including CLL cells (Illidge et al. 2012).  
Also Oblimersen, which is an antisense oligodeoxyribonucleotide blocking transcription of 
proapoptotic Bcl-2 protein can make cancer cells more sensitive to chemotherapy. Other agents, 
like flavopiridol is a synthetic flavone, which is considered as a potent inhibitor of cyclin 
dependent kinases (CDKs). Also it triggers tumor cell TP53-independent apoptosis, making it 
applicable for such CLL patients with deletion in 17p. It has to be considered also toxicity of 
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flavopiridol being significant, including tumor lysis, infections, or diarrhea (Smolewski et al. 
2013). 
Finally, the immunomodulatory agent lenalidomide, which is one of the novel drug agents used 
to treat multiple myeloma, shows also activity in CLL. Lenalidomide is an effective and well-
tolerated treatment alternative for elderly, symptomatic patients with CLL (Chen et al. 2011). 
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1.6. Aim of study/Questions worked on 
Presence of cytogenetic abnormalities is a hallmark in CLL, according to which different 
prognosis and treatment regimens should be considered. Thus the detection of theses aberrations 
is of extreme importance, and it can be performed by various techniques. GTG-banding has a 
detection rate of ~48%, even after using a suitable mitogen such as TPA. Alternative and/or 
complementary approaches are iFISH, MLPA and/or aCGH techniques. 
The aims of the present work were to: 
1. How many cryptic chromosomal aberrations in the 85 studied CLL cases could be 
detected by MLPA, in comparison with routine iFISH and GTG-banding? 
2. Could the underlying chromosomal abnormalities in CLL be precisely identified, to avoid 
misinterpretation of the prognosis so subsequently incorrect treatment regimens? 
3. What is the percentage of BIRC3 disruption in the studied 117 CLL cases, and its 
correlation with ATM deletion? 
4. Is BIRC3 disruption specific only for CLL? 
5. Is presence or absence of i(17q) in CLL able  to identify a new subgroup with more 
aggressive clinical course of the disease, and what is the best way for its detection? 
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Cytogenetics and molecular cytogenetics are and will continue to be indispensable tools in 
cancer diagnostics. Leukemia and lymphoma diagnostics are still emphases of routine 
(molecular) cytogenetics and corresponding studies of solid tumors gain more and more 
prominence. Here, first a historical perspective of molecular tumor cytogenetics is 
provided, which is followed by the basic principles of the fluorescence in situ hybridization 
(FISH) approach. Finally the current state of molecular cytogenetics in cancer diagnostics 
is discussed. Nowadays routine diagnostics includes basic FISH approaches rather than 
multicolor-FISH. The latter together with modern high-throughput methods have their 
impact on research to identify new tumor-associated genomic regions.
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Even though they have been called outdated for 
decades [1], cytogenetics and molecular 
cytogenetics still are and will stay in future 
indispensable tools in diagnostics. This state-
ment is true for clinical aspects of prenatal and 
postnatal patient care but also for patients suf-
fering from neoplasia, in particular leukemia, 
lymphoma and solid tumors, as well. In this 
review, the development of cytogenetics and 
molecular cytogenetics is summarized, the basic 
technique of molecular cytogenetics is outlined 
together with an overview on the dif-ferent 
kinds of probes available for fluores-cence in 
situ hybridization (FISH) and the current state 
of molecular cytogenetics in can-cer diagnostics 
is given. This includes espe-cially the 
commercially available probe sets applied in 
routine neoplasia diagnostics and those 
multicolor FISH (mFISH) tools used in research 
to identify new tumor-associated criti-cal 
genomic regions.
Cytogenetic & molecular cytogenetics
The history of human cytogenetics started not 
before the year 1879. At this time, micro-scopes 
of a certain quality were available, which were 
prerequisite to localize and identify 
chromosomes in a cell. All chromosomal studies 
between 1879 until approximately
1970 were retrospectively summarized as hav-
ing been performed in the ‘pre-banding era’. 
Only so-called ‘classical cytogenetic studies’
were possible in that time, that is, chromo-
somes could exclusively be distinguished by 
size and centromere index [2]; nowadays classi-
cal cytogenetics is still essential in animal [3]
and plant cytogenetics [4]. However, the 
determination of the correct modal human 
chromosome number in 1956, the first charac-
terization of inborn numerical chromosome 
aberrations (like Down syndrome) as well as the 
detection of first tumor-associated aberra-tions 
were all achieved during the early days of 
classical cytogenetics [2]. As summarized by E 
Gebhart (1989) [5], tumor-associated chro-
mosomal anomalies were indeed already recog-
nized by the first observer of human 
chromosomes, J Arnold in 1879. In 1890, it was 
D von Hansemann who highlighted that 
unusual, asymmetric mitosis can be observed 
only in cancer cells. Partially based on this, T. 
Boveri established in 1914 a ‘chromosome 
theory of cancer development’ [5], which turned 
out to be basically true many years later [6]. 
Between 1927 and 1956, there were multiple 
attempts to characterize chromosome content 
and numbers of tumor cells, which were 
basically hampered by the fact that the
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Figure 1. Schematic drawing depicting the four different kinds of 
fluorescence in situ hybridization-probes as differentiated in this 
review. (A) Locus-specific, single-copy probes, including 
subtelomeric probes. (B) Probes specific for repetitive sequences 
like telomeric (probe 1) and centromeric regions (probe 2). (C) A 
whole chromosome painting probe and
(D) partial chromosome painting probes.
constitutional chromosome number in human was not deter-
mined (correctly) at that time. It is noteworthy that the chro-
mosomal aberration being typical for chronic myelogenous 
leukemia, so-called Philadelphia chromosome, was already 
detected in the ‘pre-banding era’ (in 1960). The same holds 
true for characterization of monosomy 22 as being typically 
observed in meningioma (in 1967), and double minutes (in 
1962) later being identified as one of the cytogenetic equiva-
lents of oncogene amplification [5]. Interestingly, even G 
Mendel, the ‘father of modern genetics’ postulated the exis-
tence of linkage groups (in German ‘Kopplungsgruppe’) for 
the features he studied in peas [7]; and these linkage groups 
were nothing else than chromosomes.
Logically, after ‘pre-banding era’ came the ‘pure banding era’, 
starting with the invention of the Q-banding method by Lore 
Zech (Uppsala) in 1968 [8]. Based on this, the GTG-banding 
approach (G-bands by trypsin using Giemsa) was established in 
1971, which remained the gold standard of all cytogenetic tech-
niques until now [2,5]. Using banding cytogenetics, more chro-
mosomal abnormalities, like translocations, inversions, deletions 
and insertions, could be detected and precisely characterized, 
which was impossible before. Many tumor-specific aberrations 
were clearly identified since then, like the aforementioned Phila-
delphia chromosome which was characterized to be the result of 
a reciprocal translocation t(9;22)(q34;q11) in 1973. Also the 
acquired translocation t(8;14)(q24;q32) detected in Burkitt’s 
lymphoma in 1976 and the characterization of homogeneously
staining regions in 1978 were important findings enabled due 
to banding cytogenetics [5].
As black and white banding pattern together with chromo-
some morphology are the only two parameters that can be evalu-
ated in GTG-banding, origin of additional material in a derivative 
chromosome often remains unclear. In order to over-come this 
kind of limitations, molecular cytogenetic approaches were and 
are necessary. In situ hybridization allows for examina-tion of 
nucleic acid sequences inside cells or on chromosomes and was 
first described in 1969 as a radioactive approach. As 
nonradioactive probe labeling was not invented before 1981, 
non-radioactive FISH was needed until 1986, until it was ready 
to be used in human cytogenetics. Apart from avoidance of 
health-threatening radioactivity, FISH speeds up analysis time 
and comprises the possibility to detect several targets simulta-
neously (see below in section “FISH-techniques”) [2].
Thus, ‘pure banding era’ finished in 1986 with the first suc-
cessful molecular cytogenetic experiment on human chromo-
somes by D Pinkel and colleagues. The period since then may 
be denominated ‘banding and molecular cytogenetic era’ as 
banding cytogenetics and molecular cytogenetics 
complemented each other and became important tools on an 
equal footing in many fields of human diagnostics, including 
the care of cancer patients. Initially, there were two basic 
approaches in molecular cytogenetics: FISH and primed in 
situ hybridization (PRINS). However, the latter never 
acquired the importance of FISH, as it is much less robust and 
was never developed in a multicolor variant [2,9].
Especially important for tumor cytogenetics was inventing a 
molecular cytogenetic approach called comparative genomic 
hybridization (CGH). In CGH, two genomes are analyzed for 
gains and losses of genomic material at a low resolution of 5–10 
Mb. Even though a main feature of many solid tumors is their 
abnormal rapid in vivo growth, corresponding tumor cells often 
refrain from growing in cell culture. Thus, originally CGH gave 
first insights into chromosomal imbalances of many previously 
not cytogenetically analyzed solid tumor types. Indeed, CGH was 
applied more in research rather than as a diagnostic tool [10]. An 
advancement of this chromosome-based CGH approach is the so-
called array-CGH, providing much higher resolution of 
approximately 50 kb or even less, and being used routinely in 
clinical rather than cancer diagnostics, however, applied in 
cancer research [2,11,12].
Before discussing molecular cytogenetic applications in 
can-cer diagnostics, some aspects about how the FISH 
technique itself is performed need to be stressed.
FISH – technical aspects
DNA probes applied in FISH can be grouped in different 
ways; here we suggest doing it as follows:
.  locus-specific, single-copy probes;
.  probes specific for repetitive sequences;
.  whole chromosome painting probes (wcp);
.  partial chromosome painting probes (pcp) (FIGURE 1).
Expert Rev. Mol. Diagn. 15(4), (2015)
2. Results 25
ReviewCancer molecular cytogenetics
All four kinds of probes may be used in diagnostics and 
should be applied at least in two-color FISH experiments: one 
probe as specific for the region of interest, the second one as 
a control. Most commercially available probes are locus-
and/or centromere-specific ones (see TABLES 1–3) [2].
Besides, mFISH probe sets can be of importance in molecu-lar 
tumor-cytogenetic diagnostics, and they are even more con-
siderable in research. mFISH is defined as the simultaneous use 
of at least three different ligands or fluorochromes for the spe-
cific labeling of DNA, excluding the counterstain. The first 
commercially available and still diagnostically relevant mFISH 
probe sets were put together in 1996 by M Speicher and col-
leagues and E Schro c¨k and coworkers, respectively, enabling 
the staining of each of the 24 human chromosomes in different 
colors using wcp probes. This kind of probe set was developed in 
parallel, with slight modifications and described under dif-ferent 
names as mFISH (=multiplex FISH), SKY (=spectral 
karyotyping), multicolor FISH, COBRA-FISH (=COmbined 
Binary RAtio labeling FISH) or 24-color FISH [2]. A summary 
on possible applications besides cancer diagnostics can be found 
elsewhere [13].
As mFISH methods applying wcp probes are not suited for 
exact chromosomal breakpoint characterization, different 
approaches summarized as ‘FISH banding methods’ were 
developed. The latter ‘are any kind of FISH technique, which 
provide the possibility to characterize simultaneously several 
chromosomal subregions smaller than a chromosome arm with 
resolution down to 5 Mb (excluding the short arms of the 
acrocentric chromosomes). FISH banding methods fitting that 
definition may have quite different characteristics, but share the 
ability to produce a DNA-specific chromosomal banding’ [14]. 
The most often applied FISH-banding approach is the 
microdissection-based multicolor banding (MCB or m-band). 
Other mFISH probe sets such as for all subtelomeric regions (M-
Tel-FISH) or variants of centromere-specific multicolor FISH 
(=cenM-FISH) are commonly not applied in cancer diagnostics 
[2]. Array-CGH and next-generation sequencing (NGS) methods 
are not considered as ‘molecular cytogenetic’ approaches, even 
though some authors surprisingly do this [15]. The latter may be 
warranted by the recent description of chro-mothripsis based on 
NGS [16]. However, it has to be empha-sized that complex 
chromosomal rearrangements and even conditions like 
‘chromosome-pulverization’, which may be one step of 
chromothripsis, are known for decades already from pre-banding 
era of cytogenetics [5].
Molecular cytogenetics in cancer diagnosis
It goes without saying that in neoplasia the identification of 
cytogenetic markers1 is of high clinical significance for diag-
nostics, follow-up studies and prognosis [5,17,18]. In the first 
years after introduction of molecular cytogenetics into cancer
1A ‘cytogenetic marker’ is a set phrase in tumor cytogenetics. It can be, 
for example, a trisomy 8 as well as a translocation leading to onco-gene 
activation or a deletion leading to tumor-suppressor gene loss.
Table 1. List of most important commercially available 
fluorescence in situ hybridization-probes for leukemia.
Leukemia subtype Target region Gene
Myelodysplastic 3q26 EVI1
syndrome 4q24 TET2
5q31.2 EGR1
6p22 and 9q34 DEK/NUP214
7q22 and 7q31 RELN/TES
11q21 MAML2
16p13 and 16q22 MYH11/CBFB
20q12 and 20q13.12 PTPRT/MYBL2
Chronic myeloid 4q12 FIP1L1/CHIC2/PDGFRa
leukemia 5q32~33 PDGFRB
9p24 JAK2
9q34 and 22q11 BCR/ABL
11q22 ATM
17p13 P53
Acute myeloid 3q26 EVI1
leukemia (AML) 4q12 KIT
5q31.2 EGR1
5q32 CSF1R
5q35 NPM1
6p22 and 9q34 DEK/NUP214
6q23 MYB
6q27 MLLT4
7q22 and 7q31 RELN/TES
9p24 JAK2
9p21.3 MLLT3
11p15 NUP98
11q23 MLL
15q24 and 17q21.2 PML/RARa
16p13 and 16q22 MYH11/CBFB
20q12 and 20q13.12 PTPRT/MYBL2
21q22 ERG
22q22 and 8q21 RUNX1/RUNX1T1
Chronic lymphocytic 3q26 TERC
leukemia 5q32 CD74
6q21 SEC63
6q23 MYB
11q22 ATM
11q13 Cyclin D1
11q22 and 18q21 BIRC3/MALT1
12q13 GLI
13q14.3 DLEU2 or D13S25
14q32 and 11q13 IGH/CCND1
17p13 P53
19q13 BCL3
Acute lymphocytic Xp22.3 CRFL2
leukemia Xp22.3 P2RY8
1p32 SIL/TAL1
1q23 and 19p13.3 PBX1/TCF3
4q21 and 11q23 MLL/AFF1
5q35 TLX3
6q23 MYB
7q34 TCRB
8q24 C-MYC
9p21 P16 or CDKN2A
9p13 PAX5
9q34 and 22q11 BCR/ABL
10q23 PTEN
10q24.3 TLX1
11q23 MLL
12p13 and 22q22 TEL/AML1
14q11 TCR A/D
14q32.13 TCL1
14q32.3 IGH
19p13 E2A
22q22 and 8q21 RUNX1/RUNX1T1
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Table 2. List of most important commercially 
available fluorescence in situ hybridization-probes for 
lymphoma.
Lymphoma subtype Target region Gene
Anaplastic large-cell l 2p23 ALK
5q35 NPM1
Burkitt l 2p11 IGK
8q24 C-MYC
14q32.3 IGH
17p13 P53
21q11 IGL
Diffuse large B-cell l 2p16 REL
2p11 IGK
3q27 BCL6
8q24 C-MYC
9p21 P16 or CDKN2A
14q32 and 18q21.33 IGH/BCL2
17p13 P53
19q13 BCL3
21q11 IGL
Follicular l 3q27 BCL6
6q23 MYB
9p21 P16 or CDKN2A
14q32 and 18q21.33 IGH/BCL2
17p13 P53
Mantel cell l 5q32 CD74
9p21 P16 or CDKN2A
11q22 and 18q21 BIRC3/MALT1
13q14.3 DLEU2
14q32 and 11q13 IGH/CCND1
17p13 P53
19q13 BCL3
Multiple myeloma 1q21 and 1p36 c-MAF/SRD
1q21 and 8p21 c-MAF/n.a.
4p16.3 FGFR3
5q32 CD74
6q23 MYB
11q22 ATM
13q14 DLEU2
14q32 and 4p16 IGH/FGFR3
14q32 and 11q13 IGH/CCND1
14q32 and 16q23 IGH/MAF
14q32 and 20q12 IGH/MAFB
15q22 and 9q34 n.a. ! detection
of hyperdiploidy
17p13 P53
Others 2p23 ALK
3q12 TFG
3q27 BCL6
5q35 NPM1
6q23 MYB
10p11.2 KIF5B
11q21 and 18q21 API/MALT1
11q22 ATM
13q14.3 DLEU2
14q32 and 18q21.33 IGH/BCL2
17p13 P53
l: Lymphoma; n.a.: Not available.
diagnostics, FISH was most often considered as a tool to con-
tinue and refine previous cytogenetic studies. This way to 
choose and apply corresponding FISH-probes represents still 
a major part of molecular cytogenetic diagnostics [19– 21]. 
Besides, molecular cytogenetics is more and more performed 
indepen-dently from banding cytogenetic analyses in all kinds 
of tumors, too [22]. This development was, among others, sup-
ported by the fact that every cytogenetic analysis is in need of 
dividing cells to produce metaphase spreads. In other words, 
time-consuming cell culture is necessary. Thus, interphase-
directed FISH (iFISH) analyses on tumor cell smear, touch 
preparations or tissue sections are more and more in use with 
the goal to achieve a quick result [23– 25].
FISH approaches are especially suited to characterize chro-
mosomal and subchromosomal copy number changes and gene 
fusions due to translocations or other rearrangements. All these 
features are characteristically found acquired aberrations in
cancer [5,18,19].
In the following, different FISH-probe types and possible 
applications in cancer diagnostics are summarized to the best 
of our knowledge. Various FISH probes may be applied in a 
specific case due to a finding in banding cytogenetics, indica-
tion specific and/or in follow-up studies.
Application of centromeric probes
Exclusive probes directed against the centromeric regions of one 
specific human chromosome, each, are available for all human 
gonosomes and most autosomes except for #5, #13, #14, #19, 
#21 and #22 [26]. As centromeric probes provide dot-like signals 
after FISH, they can be evaluated in metaphase and interphase 
easily. They are commercially available and highly suited to 
determine and/or confirm mono-, tri- or tetrasomies of single 
chromosomes in tumor cells. Due to often low banding resolu-
tion of tumor chromosome, preparations such a metaphase-
directed FISH test may even be necessary in routine diagnostics, 
for example, to determine or confirm the origin of a trisomic 
chromosome derived from C-group. Numerical aberrations may 
be observed for practically all human chromosomes in cancer. So 
just three examples where these probes may be of importance are 
given here as monosomy 7, trisomy 8 or tetrasomy 8, which may 
all be present in acute leukemia [27,28]. Another important field 
where especially gonosomal centromere-directed probes are 
regularly applied is follow-up of sex-mismatched bone marrow 
transplantation [29,30].
For application of all centromeric probes, one possible pitfall 
has to be highlighted here: centromeric regions may be subject to 
so-called chromosomal heteromorphisms. There are reports on 
false-positive and false-negative results after pure iFISH 
diagnostics using this kind of FISH-probes [26]. Thus, centro-
meric probes should only be applied if metaphase FISH was 
done at least once with the corresponding probes. Nowadays, 
locus-specific probes (see below) suited for iFISH are available 
for all human chromosomes, which should preferably be applied 
in all neoplastic samples of patients where no informa-tion is 
available on potential centromeric heteromorphisms.
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Table 3. List of most important commercially 
available fluorescence in situ hybridization-probes for 
solid tumors.
Tissue type probe Target region Gene
to cancer
Bladder 9p21 P16 or CDKN2A
17p13 P53
Bone and soft tissue 1p36.2 and 3q25 CAMTA1/WWTR1
1p36 PAX7
2q33 CREB1
2q36 PAX3
3q12 TFG
6p21 PHF1
7p21 ETV1
9q22 NR4A3
11p15.5 CARS
11p13 WT1
11q24 and 22q12 FLI1/EWSR1
12q13 DDIT3
12q13~q14 CDK4
12q14 HMGA2
12q15 MDM2
13q14 FOXO1
16p11 FUS
17q21 and 22q13 COL1A1/PDGFB
18q11.2 SS18
21q22 ERG
22q12 EWSR1
Breast 1q32 MDM4
1q41 CENPF
3q26 SOX2
5q31.2 EGR1
6q23 MYB
6q25 ESR1
7p12 EGFR
8p11.2 FGFR1
8q24 C-MYC
10q23 PTEN
10q26 FGFR2
11q13 CCND1
11q22.3 ATM
12p12 KRAS
12q14 HMGA2
15q25 NTRK3
17p13.1 P53
17q11.2~12 HER2/NEU1/ERBB2
17q21~22 TOP2A
20q13 ZNF217
CNS 1p36.2 and 3q25 CAMTA1/WWTR1
1p36 MEGF6
1q25 ABL2
1q41 CENPF
2p24 NMYC
3p25 VHL
3q26 SOX2
6q22 ROS1
7p11.2 EGFR
9p21 CDNK2A
10q23 PTEN
Table 3. List of most important commercially 
available fluorescence in situ hybridization-probes for 
solid tumors (cont.).
Tissue type probe Target region Gene
to cancer
12q13~q14 CDK4
15q25 NTRK3
17p13 P53
19p13 ZNF44/ZNF
19q13 CRX
Colorectal 3q26 SOX2
6q23 MYB
6q24.3 RREB1
7q34 BRAF
10q23 PTEN
12p12 KRAS
17p13.1 P53
18p11.32 TYMS
Esophagus 8q24 C-MYC
9p21 P16 or CDKN2A
17p13.1 P53
17q11.2~12 HER2/NEU1/ERBB2
18p11.32 TYMS
20q13 ZNF217
Eye 1q32 MDM4
13q14 RB1
Head and neck 1q41 CENPF
3p25 VHL
5q32 CD74
11q21 MAML2
12p13.3 FOXM1
19p13.2 BRD4
Kidney Xp11.23 TFE3
3p25 VHL
3p14 FHIT
6p21 TFEB
7q31 MET
10q23 PTEN
17p13 YWHAE
Liver 4q12 KIT
8q24 CMYC
9p21 P16
11q13.3 FGF3,4,19
12p12 KRAS
17p13.1 P53
18q21 BCL2
Lung 1q32 MDM4
2p23 and 2p21 ALK/EML4
3p14 FHIT
3q12 TFG
3q26 SOX2
4q12 PDGFRA
5q32 CD74
6q22 ROS1
7p12 EGFR
7q34 BRAF
10p11.2 KIF5B
10q26 FGFR2
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Table 3. List of most important commercially 
available fluorescence in situ hybridization-probes for 
solid tumors (cont.).
Tissue type probe Target region Gene
to cancer
Skin (melanoma) 6q23 MYB
6p25 RREB1
7p21 ETV1
7q34 BRAF
9p21 P16
10q23 PTEN
11q13 CCND1
22q12 EWSR1
Stomach 3q26 SOX2
4q12 KIT
4q12 PDGFRA
7q31 MET
8q24 CMYC
10q23 PTEN
10q26 FGFR2
11q22 and 18q21 BIRC3/MALT1
17p13.1 TP53
17q21 ERBB2
18p11.32 TYMS
Ovary 3q26 PIK3CA
8q24 CMYC
9p21 P16
10q26 FGFR2
11q13 CCND1
12p12 KRAS
17p13.1 P53
19q13 CRX
20q13 NCOA3(AIB1)
Pancreas 5q32 CD74
6q24.3 RREB1
7q34 BRAF
9p21 P16
10q23 PTEN
11q22.3 ATM
12p12 KRAS
17q13 P53
Prostate Xq12 AR
3p14 FHIT
3q27 ETV5
7p21 ETV1
8q24 C-MYC
9p21 P16
10q23 PTEN
12p13.3 FOXM1
12q13q14 CDK4
17p13.1 P53
21q22 ERG
Thyroid gland 1q22~q23 NTRK1
2q13 PAX8
3q12 TFG
7q34 BRAF
10q11.2 RET
10q23 PTEN
Table 3. List of most important commercially 
available fluorescence in situ hybridization-probes for 
solid tumors (cont.).
Tissue type probe Target region Gene
to cancer
Uterus 3q26 PIK3CA
5q32 CSF1R
6p21.3 PHF1
7p15 JAZF1
8q24 CMYC
9p21 P16
10q23 PTEN
10q26 FGFR2
12p12 KRAS
17p13 YWHAE
17p13.1 P53
17q12 HER2/NEU1/ERBB2
Others 1p36 SRD
1p32 and 1q21 CKS1B/CDKN2C
3p14 FHIT
3q26 TERC
5p15 TERT
6q22 MET
7q31 ROS1
12p13.3 FOXM1
Application of locus-specific probes
In TABLES 1–3 major parts of the presently commercially 
available locus-specific probes for metaphase FISH and 
iFISH applica-tions in human cancer diagnostics are listed 
[31– 37]. According to tumor type, application of one or more of 
these probes may be indicated.
The sheer amount of available locus-specific probes 
hampers a detailed discussion of each of them in this review. 
Use of locus-specific probes in neoplasia was reviewed before 
for leuke-mia [29,38– 44], lymphoma [44– 46] and solid tumors 
[44,47], like skin [44,47– 49], lung [50] or breast cancer [51,52].
However, the commercially available probes can be 
catego-rized as follows (FIGURE 2):
. dual-color break-apart probes, detecting oncogene activa-
tion [5] by disruption of the corresponding tested gene;
. dual-color (dual) fusion probes, which normally are separated 
from each other in the human genome, but can come into close 
proximity due to different kinds of rearrangements, leading in 
the end also to oncogene activation [5];
. dual-color probes meant to detect deletion of tumor-
suppressor genes [5];
. dual-color probes for detection of copy number alterations of 
parts of the genome – especially oncogene amplification [5];
. dual-color probes just for detection of copy number altera-
tions of major parts of or the entire genome (hypo- or 
hyper-diploidy [5]) localized at different chromosomes.
The same probe may be suited to detect oncogene disruption,
translocation and amplification or hyper-/hypodiploidy.
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Figure 2. Schematic depiction of how locus-specific probes are normally combined in commercially available probe sets; the signal 
distribution as observed in an normal interphase cell is shown in the upper, the abnormal situation in the lower row.
(A) Dual-color break-apart probe; (B) dual-color dual fusion probe; (C) dual-color probe-set for detection of a tumor-suppressor 
gene deletion; (D) dual-color probe-set for detection of an oncogene-amplification – in D1 a gene amplification due to double 
minutes and in D2 a corresponding amplicon due to a homogeneously staining region is shown; and (E) dual-color probe-set for 
detection hypo- or hyperdiploidy – here a triploidy is detected.
Here it must especially be stressed that molecular cytogenetic 
methods (except for CGH) are single-cell-directed tests. Thus, 
low-level mosaics can be detected that may be missed by 
molecular genetic approaches [53]. On the other hand, molecu-lar 
approaches have the advantage of being inexpensive and able to 
cover more targets at once. An approach that could the-oretically 
have the potential to partially replace (molecular) cytogenetics in 
tumor diagnostics is multiplex ligation-dependent probe 
amplification. This PCR-based technique can be used to screen 
for fusion genes, point mutations and copy number variations 
[54]. However, it has to be checked carefully when information on 
low-level mosaics can be renounced, and it is necessary for 
accurate patient care. This statement is true for all molecular 
approaches testing millions of cells at a time. Best may be to 
combine the available approaches in a tumor-specific scheme 
such as, for example, recently suggested for chronic lymphocytic 
leukemia [39].
Application of whole chromosome painting probes
Metaphase-directed two- or three-color FISH using wcp
probes may be necessary in cancer diagnostics regularly, 
especially after derivative chromosomes were detected during 
banding cyto-genetic analyses [55]. Still banding cytogenetics 
and/or the tumor-subtype need to provide clear hints that 
correct wcp probes are chosen for further characterization of 
an acquired derivative chromosome; otherwise, if available, 
mFISH using all wcp probes in different fluorochrome 
combinations may be indicated [56,57]. Of course, wcp probes 
may also be combined with other probes like pcp-, locus-
specific or centromeric ones. Finally, it is a truism that wcp-
and pcp-probes are not suited for routine iFISH studies [58].
Application of mFISH probe sets
In neoplasia, characterization of complex rearrangements (CCR) 
may also be necessary in routine diagnostics [57]. However, as 
CCR are considered to implicate an adverse diagnostics, often no
further analyses are performed [5,17,18]. Besides, it is a matter of 
financial issues and of the technical possibilities available in the 
laboratory executing the diagnostics if expensive mFISH studies 
can be applied in a specific case. In a worldwide perspective, the 
majority of laboratories and oncologists will not be able to per-
form mFISH studies on a routine bases. Some countries in West-
ern Europe, Northern America and some other more wealthy 
places around the world may be able to apply them on a routine 
base at present; these may be the same which can offer array-
CGH and NGS as a routine setting [59– 62].
In majority of cases, mFISH approaches (as well as array-
CGH and NGS) will be applied only in individual cancer 
cases in research-associated settings [63– 67]. Besides mFISH 
using wcp probes, also FISH-banding approaches and other 
probes will be used to resolve the individual case [68].
Clinical genetic aspects of molecular cytogenetics 
diagnostic performed in cancer diagnosis
Any kind of FISH study performed in a case with diagnosis can-
cer needs to be done according to the results of tumor cytogenet-
ics and/or the input of the referring clinician. Genetic counseling 
will not be necessary in most of neoplastic cases. However, 
excep-tions are the hereditary cancers, like breast cancer [69– 71].
Moreover, one has to consider that during cytogenetic and 
molecular cytogenetic analysis incidental findings are possible. 
Mosaic Turner or Klinefelter syndrome or carriers of small super-
numerary marker chromosomes may be detected [71,72]. Such 
findings, even though being rare, also should be expected by the 
clinician when a tumor-cytogenetic analysis has been requested.
Expert commentary
Molecular cytogenetics, together with cytogenetics provided, pro-
vides and will provide in future major input into the characteriza-
tion of molecular defects in neoplasia. Morphological and clinical 
data, together with (molecular) cytogenetics and, as far as available, 
data from more sophisticated molecular approaches,
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should all be considered to obtain correct diagnoses of studied 
malignancies. However, as in majority of the world, banding 
cytogenetics supplemented by the use of locus-specific probes is 
that what routine malignancy diagnostics consists of we clearly 
disagree with the statement of others [44] that FISH and mFISH 
approaches are ‘early methods’ for routine cancer diagnostics and 
‘recent high throughput genomic methods’, that is, array-CGH
and NGS are the new routine ‘molecular cytogenetic’ methods. 
Array-CGH and NGS are wonderful research tools. They will for 
sure lead in future to more insights into altered genome structure 
of malignancies. And maybe in some wealthy ‘Western’ countries 
these approaches, together with expensive mFISH techniques, 
may reach routine diagnostic status. The main importance of 
these sophisticated approaches in terms of implementation, and 
especially interpretation, will be the identification of new tumor-
relevant genetic markers. The latter will be accessible by targeted 
and simpler tests, later.
Five-year view
In future, cytogenetics and molecular cytogenetics still will be 
a standard approach in cancer diagnostics. Specifically, the
impact of metaphase as well as interphase-directed locus-specific 
FISH-probes will increase, especially as it can also be combined 
with immunohistochemistry [73]. This is among others 
highlighted by the fact that more and more companies enter the 
market offering increasing portfolios of tumor-related FISH-
probes [31– 37]. Thus, we expect molecular cytogenetics to remain 
a stable field in terms of necessity and application in cancer 
diagnostics. Thus, we suggest that not only for the next 5 years 
but for definitely longer, molecular cytogenetics would be a key 
diagnostic, prognostic and follow-up tool in routine.
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Key issues
.
Molecular cytogenetics evolved in 1986 from cytogenetics.
. Cytogenetics started to gain major relevance in cancer diagnostics after identification of the first tumor-associated chromosomal 
aberration in 1960.
. Molecular cytogenetics uses different kinds of probes, such as locus-specific ones, whole and partial chromosome painting probes 
and probes specific for repetitive sequences.
. Two-color fluorescence in situ hybridization (FISH) is applied in routine cancer diagnostics, while multicolor FISH (mFISH) methods 
are applied more in research-associated settings.
. Locus-specific probes are routinely applied for the detection of tumor-suppressor gene deletion, oncogene amplification and/or 
gene fusions, as well as hypo- and hyperdiploidies.
.  Molecular cytogenetics routine applications are used in leukemia, lymphoma and solid tumor diagnostics.
.
Cytogenetics and molecular cytogenetics is single cell directed and thus able to detect even acquired low-level mosaics.
.
One has to be prepared to meet also in cancer diagnostics from time to time hereditary cases, which need special attention.
. mFISH as well as array-comparative genomic hybridization and next-generation sequencing are highly suited for research settings, 
able to identify new tumor-relevant genetic markers.
. mFISH, array-comparative genomic hybridization and next-generation sequencing are and will in the near future be too expensive 
to become routine cancer diagnostic tools from a worldwide perspective.
.  Cytogenetics and molecular cytogenetics are and will stay in the future indispensable tools in cancer diagnostics.
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B ackground Chronic lymphocytic leukemia (CLL) is considered as the 
most common adult leukemia in Western countries with 
an estimated incidence of 5.8 in men and of 3.0 in women 
per 100,000 individuals and per year. It predominantly af-
fects persons with more than 50 years of age  [1,2]. A 
hall-mark of CLL is the presence of cytogenetic 
abnormalities; the latter help to estimate a patient’s 
prognosis more ac-curately and also may provide insights 
into disease patho-genesis  [3]. However, banding 
cytogenetics can only detect aberrations in ~30% of CLL 
samples  [4]. Still, according to molecular (cyto)genetic 
data the major recurrent aberra-tions are: 
 
(i) Deletions in 13q14 (50-60% of the samples) 
associated with a good prognosis, as are deletions in 
14q32.33 (12-15% of the samples);   (ii) Trisomy 12 (15-25%) associated with 
intermediate prognosis; and   (iii) Deletions in 11q22 (ATM) (10-20%) or 17p13 
(TP53) (5-10%) and/or recurrent balanced 
translocations go together with adverse 
prognosis  [4- 9];   (iv) Less frequently observed aberrations in CLL are 
deletions in 6q associated with intermediate 
prognosis, 9p21 and 10q23, total or partial 
trisomies of chromosomes 3, 8, 18, or 19, and 
duplications in 2p24, the prognostic significance for 
these aberrations is unknown  [1,10,11].  
 
These aberrations were either detected applying cytogen-
etics and/or interphase fluorescence in situ hybridization 
(iFISH)  [3] or more recently multiplex ligation-dependent 
probe amplification (MLPA)  [7]. While iFISH provides in-
formation only for a limited number of genomic targets at the 
same time  [1,5,7] MLPA can detect copy number al-
terations, methylation pattern changes and/or even point 
mutations simultaneously in multiple target regions  [7,12]. 
Still iFISH can more reliably detect low level mosaics and 
osaics of mono- and biallelic deletions m  [13]. In this study the efficiency of MLPA was compared 
with yet in our lab routinely performed cytogenetic and 
iFISH diagnostics of CLL. Based on the obtained results a 
new diagnostic scheme is proposed combining MLPA and 
iFISH leading to a more comprehensive characterization 
of each individual sample.  
R esults 85 samples of patients suffering from CLL (Additional file  
1: Table S1 and Additional file  2: Table S2) were stud-ied 
here. Overall, including results from all here applied tests, 
chromosomal aberrations were detected in 70/85 (~85%) of 
the studied CLL-samples (Additional file  1: Table S1 and 
Additional file  2: Table S2). As summarized 
   
 
in Figure  1 between 0 and 8 aberrations were detectable 
per case. One chromosomal rearrangement per sample 
could be found most often (40%), followed by no aberra-
tion at all and three aberrations per sample. Four or more 
aberrations per sample were found in less then 10% of the 
ases. c Overall, 163 aberrations were detected in the 85 studied 
samples (Table  1, Additional file  2: Table S2). Cytogenet-
ics revealed aberrant karyotypes in 15 (~22%) of the 67 
samples where corresponding analyses was successful 
(Additional file  1: Table S1). In parts the cytogenetic find-
ings could be substantiated by iFISH and or MLPA. As no 
corresponding probes were included neither in routine iFISH 
nor in MLPA, 15 (~9%) of the 163 detected ab-errations 
were found additionally by cytogenetics (Table  2). 
Interestingly, in sample 57 which presented with 5 
chromosomal aberrations after banding cytogenetics no 
aberrations could be detected at all by iFISH or by MLPA. 
Other samples gave either no, a normal cytogenetic result or 
a result which also was confirmed by MLPA and/or iFISH 
Additional file (  1: Table S1). Concerning the detection rates, the applied MLPA test 
found ~58% and routine iFISH ~61% of the 163 
aberrations (Table  1, Additional file  2: Table S2). 
del(13)(q14.3q14.3) was most frequently found, i.e. in 
~28% of the samples), followed by del(11)(q22.3q22.3) in 
~9%, del(14)(q32q32) in ~8%, and del(13)(q14.2q14.2) 
nd del(17)(p13.1p13.1) in ~6% of the samples, each. a Discordant results of MLPA and routine iFISH were in 
parts due to the different target regions covered by the 
tests; thus e.g. del(14)(q32q32) were only detectable by 
routine iFISH. On the other hand, MLPA detected add-
itional aberrations in 22 samples, three of the patients 
being without any aberrant findings according to routine 
FISH (Additional file i  2: Table S2, cases 68–70). In Table  3 thirteen samples are listed, which had low 
level mosaic aberrations based on routine iFISH and were 
not picked up by MLPA. In contrary in Table  4 twelve 
other samples with similar low level mosaics are listed, 
which were picked up by MLPA.              
Figure 1 Number of aberrations present per sample as found in 
this study after application of all mentioned methods (banding 
cytogenetics, iFISH and MLPA) – values given in percent. 
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Table 1 Summary of 99 aberrations as detected by MLPA 
and 146 ones as detected or confirmed by iFISH; samples 
contributing to the discordant results of MLPA and iFISH are 
arked with asterisk *, ** or ‘plus-sign’ + m Affected regions Genes Detected Detected
  in MLPA in iFISH
    
amp(2)(p24.3p24.3) MYCN 3 3
amp(2)(p23.2 ~ 23.1p23.2 ~ 23.1) ALK 3 3
del(6)(q21q21) FYN 1 1
del(6)(q23.3q23.3) MYB 2 2
del(6)(q25.1q25.1) ESR1 1 1
del(6)(q27q27) SMOC2 1 1
amp(6)(q27q27) SMOC2 1+ 0
amp(8)(q24.21q24.21) MYC 1 1
t(9;22)(q34;q11) BCR and ABL n.a. 1
del(11)(q22.3q22.3) ATM 12 14*
+12 ETV6, CCND2, 4 6*
 MDM2   
del(13)(q14.2q14.2) RB1 10 11**
del(13)(q14.2q14.2)x2 RB1 1 10**
del(13)(q14.3q14.3) DLEU1, DLEU2, 35 46*/**
 MIR15A   
del(13)(q14.3q14.3)x2 DLEU1, DLEU2, 7 14**
 MIR15A   
del(14)(q32q32) IGH n.a. 13
rea(14)(q32.33) - > t(14;?) IGH n.a. 2
rea(14)(q32.33) - > ? + 14 IGH n.a. 1
del(17)(p13.1p13.1) TP53 9 10*
amp(17)(q25.1q25.2) UNC13D 2 2
amp(18)(p11.21q11.21) DCC 2+ 1
amp(18)(q21.2q21.2) RNMT 2+ 1
a mp(21)(q22.12q22.12) RUNX1 2 2
Those with * are detailed in Table  2, those with ** in Table  4. Those with + 
could either not be tested in iFISH due to lack of corresponding probe or, in the 
two of the tested samples MLPA could not be confirmed by iFISH (routine and 
confirmatory together), most likely due to too large FISH-probe size.  
Table  5 highlights 19 samples which were detected as 
carrying deletions in 13q14.2 and/or 13q14.3 according to 
MLPA and iFISH. Still iFISH revealed that there was a 
mix of monoallelic and biallelic deletion or only biallelic 
deletion, which could not always be detected by MLPA 
(Additional file  2: Table S2). Only such cases which had 
100% biallelic deletions could be identified undoubtedly 
(e.g. sample 30); others showed biallelic deletions in 
LPA but were indeed a mix of mono- and biallelic ones. M Finally, three copy number alterations found by MLPA 
could not be substantiated by additional iFISH studies 
samples 65–67; Additional file (  2: Table S2). In Figure  2 a flow is suggested how a CLL-characterization could 
be performed most comprehensively and straight 
   
 
Table 2 Aberrations only detected by banding 
ytogenetics in 9 samples of the present study c Sample number Aberration only visible in GTG-banding [%]
  
1 del(5)(p1?3)[33] 
32 -Y[44]
34 -Y[50]
38 t(3;?)(p21;?)[43] 
41 -Y[80]
57 der(1)t(1;4)(q1?2;q?31)[90]
 der(4)t(4;?10)(q?31;q24)[90]
 ?der(10)t(10;16)(q24;p?11.2)[90]
 der(15)t(1;15)(q1?2;q1?2)[90]
 der(16)t(15;16)(q1?2;p?11.2)[90]
58 der(2)t(2;13)(q?37;q?14)[21]
 ?del(6)(p?23)[21] 
61 t(3;?)(q2?9;?)[22] 
 −7[22]
70 ?add(1q)(q4)[50] 
  
 
forward. Figure  3 shows how cases would have been 
grouped if only cytogenetics, only MLPA or only iFISH 
would have been done. Tables  6, 7 and  8 highlights how 
a step by step characterization and corresponding new re-
sults of would change the prognosis of the 95 studied 
cases.  
D iscussion When diagnostic screening for acquired genetic alter-
ation in hematological malignancies is to be done, band-
ing cytogenetics is still the gold standard, as it enables  
Table 3 Detailed results in samples contributing to the 
discordant results of MLPA and iFISH marked with 
sterisk * in Table a  1 Affected regions Genes Sample iFISH
  number mosaic [%]
 
del(11)(q22.3q22.3) ATM 1 30
del(11)(q22.3q22.3) ATM 2 33
+12 ETV6, CCND2, MDM2 3 15
+12 ETV6, CCND2, MDM2 4 31
del(13)(q14.3q14.3) DLEU1, DLEU2, MIR15A 5 18
del(13)(q14.3q14.3) DLEU1, DLEU2, MIR15A 6 10
del(13)(q14.3q14.3) DLEU1, DLEU2, MIR15A 7 10.5
del(13)(q14.3q14.3) DLEU1, DLEU2, MIR15A 8 12
del(13)(q14.3q14.3) DLEU1, DLEU2, MIR15A 9 18.5
del(13)(q14.3q14.3) DLEU1, DLEU2, MIR15A 10 25
del(13)(q14.3q14.3) DLEU1, DLEU2, MIR15A 11 34
del(13)(q14.3q14.3) DLEU1, DLEU2, MIR15A 12 34
del(17)(p13.1p13.1) TP53 13 11.5
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Table 4 Detailed results in samples with concordance of 
MLPA and routine iFISH results but mosaic rates below 
0% according to iFISH 4 Affected regions Genes Sample iFISH
  number mosaic [%]
  
del(11)(q22.3q22.3)   ATM 14 23.5
del(11)(q22.3q22.3) ATM 15 24
del(11)(q22.3q22.3) ATM 16 11
del(13)(q14.3q14.3) DLEU1, DLEU2, MIR15A 1 30
del(13)(q14.3q14.3) DLEU1, DLEU2, MIR15A 2 18
del(13)(q14.3q14.3) DLEU1, DLEU2, MIR15A 4 20
del(13)(q14.3q14.3) DLEU1, DLEU2, MIR15A 14 34
del(13)(q14.3q14.3) DLEU1, DLEU2, MIR15A 17 20
del(17)(p13.1p13.1) TP53 1 16
del(17)(p13.1p13.1) TP53 12 21
del(17)(p13.1p13.1) TP53 18 19
del(17)(p13.1p13.1) TP53 19 36
          
 
Table 5 Combination of biallelic and/or monoallelic 
deletion del(13)(q14.2q14.2) and del(13)(q14.3q14.3) – 
hich is not clearly resolved by MLPA w Sample iFISH mosaic [%]  iFISH mosaic [%]
number del(13)(q14.2q14.2) 
 
 del(13)(q14.3q14.3)
    
Biallelic   Monoallelic 
   
 
the untargeted search for gross chromosomal aberrations  
[14]. Malignant CLL cells derived from bone marrow are 
known to have a low mitotic index and in many cases only 
cytogenetically normal cells can be analyzed  [4]. Thus, 
iFISH and MLPA are routinely applied additionally to or 
ven as a replacement in tumorcytogenetics of CLL e  [7,15]. In this study, after directed diagnostics for 37 genetic 
loci (MLPA and routine iFISH together), still ~18% of the 
samples remained without an identified tumor marker. As 
highlighted by samples 32, 34, 41, 36 (see as well  [16]) 
38, 57, 58, 61 and 70 this can be due to unusual, not by 
tar-geted routine tests covered chromosomal aberrations; 
be-sides submicroscopic aberrations like point mutations  
[2] could be present in those ‘normal’ samples. 
Interestingly, in over 40% of the studied cases more than 
only one chromosomal aberration was identified (Figure  
1). This may reflect in parts the slow progress of CLL. I.e. 
the ma-lignancy is detected after acquiring multiple 
aberrations and not as early as e.g. chronic myelogeneous 
leukemia (CML), which is already connected with severe 
clinical signs when only a t(9;22) is found, which is the 
nly aber-ration in majority of the CML-cases o  [17]. As mentioned above, MLPA and routine iFISH are tar-
geted tests, both. As they cover in parts different loci it 
was not unexpected that they have different detection 
rates. However, one would expect that iFISH technique 
underestimates the genomic complexity in CLL  [1]. Still 
it is striking that the routine iFISH test found 61% of the 
163 aberrations while MLPA only detected 58%, even 
though routine iFISH applied only 5 probes and MLPA 
ad more than 7 times more, i.e. 37 target regions.  Monoallelic Biallelic 
 
deletion 
 
deletion
 
  deletion 
 
deletion
 
2 0 0 18 14
4 45 0 20 0
12 52 38 34 0
13 0 0 0 98.5
20 0 0 0 94
21 50 30 0 91
22 0 0 5 75
23 0 0 5 81
24 36 41 16 71
25 66 21 18 77
26 0 0 25 65
27 34 27 36.5 24
28 0 0 81 7
29 58 24 86 9
30 0 0 0 100
54 41 39 97 0
55 73 5 85 0
56 22 58 12 66
63 51 38 90 0
      
h Concerning detection of low level mosaics (10% up to 
36% of the cells being aberrant) this study showed that 
there are about alike amounts of cases being detectable 
and being missed by MLPA (Tables  3 and  4). There 
were cases detectable by MLPA with aberrant cell clone 
sizes down to ~10% according to iFISH (sample 16) and 
such being not detectable (samples 6, 7, and 8). To the 
best of our knowledge there are only few previous  [18- 
20] and no systematic studies for the detection rates of 
low level mosaic in MLPA. Véronèse et al.  [7] suggested 
that all false-negative cases occur in samples with only 
12-21% of aberrant cells; thus they considered MLPA 
detection to be reliable when the fraction of aberrant cells 
is 25-30%, which is definitely less sensitive than iFISH 
detection. Overall, this problem has to be kept in mind 
hen doing MLPA exclusively in routine diagnostics. w Still, the findings of this study are in concordance with 
Stevens-Kroef et al.  [21] who claimed an almost perfect 
correlation between MLPA and iFISH, as long as identical 
genetic regions are tested in MLPA and iFISH. However, bi- 
and monoallelic deletions coming together in one sam-ple 
are not considered in this kind of comparison. Still, all apart 
from three MLPA findings not detectable in the 
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Figure 2 Suggestion how to proceed when doing MLPA as a primary test after GTG-banding: in case MLPA finds a tumor marker 
with adverse prognosis no further iFISH analyses is necessary. In case of an MLPA result suggesting intermediate, unclear or good 
iFISH for 3 to 6 target regions should be done. A probe for 6q may be also used; however, as case with a del(6q) are rare we would 
not recommend it at present as really indicated to be applied. According to the obtained results cases need to be regrouped. Finally, 
iFISH can be used to subclassify cases with good prognosis into such with favorable and unfavorable good prognosis.                      
Figure 3 Detection rates of cytogenetics, MLPA and iFISH as standalone approaches are depicted and compared with overall 
result combining all three tests as suggested in Figure  2; the corresponding results obtained in the 85 cases were aligned with 
and are expressed as the resulting prognostic relevance of the identified chromosomal aberrations. 
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T able 6 Samples from Additional file  2: Table S2 are listed according to the groups suggested in Figure  2 Results according to Adverse prognosis Intermediate or Good prognosis including groups No aberrations
MLPA  unclear prognosis “favorable” and “unfavorable”  
     
2*, 4*, 13*, 20*, 21*, 22*, 23*, 25*, 26*, Samples 1, 10, 12, 14, 15, 16, 17, 18, 19, 5, 37, 62, 68 3, 6, 7, 8, 9, 11, 31, 32, 33, 36,
 24, 34, 35, 38, 39, 54, 58, 61,  27*, 28*, 29*, 30*, 40, 41, 42, 43, 44, 57, 59, 60, 70, 71, 72, 73, 74,
 63, 64, 65,  45, 46, 47, 48, 49, 50, 51, 52, 53, 55*, 75, 76, 77, 8, 79, 80, 81, 82,7
83, 84, 85    56*, 66, 67, 69
Number of samples 20 4 32 29 
per group (absolute)     
Number of samples 23.5 5 37.5 34 
p er group (percent)     
Samples marked with * have biallelic deletion in 13q14 as substantiated by iFISH or deletion of 13q14.2 and 13q14.3, thus going from favorable to 
unfavorable subgroup within good prognosis group after iFISH (see Table  7). Figures printed not bold and not in italics are case numbers; figures 
printed bold and in italics are absolute numbers of samples or same numbers in percent. 
 
applied routine iFISH setting could be verified by subse-
quent targeted iFISH. In the not verified cases this can be 
due to too small size of the detected copy number alter-
tion, not resolvable by iFISH. a It is well known that there are different clinical prog-
noses if a del(13)(q14.3q14.3) comes mono- or biallelic 
and alone or together with a del(13)(q14.2q14.2): larger 
deletions like del(13)(q14.2q14.3) and biallelic deletions 
have shorter time to first treatment  [1,22,23]. To get re-
liable information for this question a combination of 
LPA and FISH is necessary. M According to Campregher and Hamerschlak  [2] the de-
tected aberrations can be grouped in such with adverse, 
intermediate, good prognosis. Those cases with good prog-
noses are further subdivided in such cases with favorable and 
such with less favorable outcome. Especially cases with 
adverse prognosis have influence on the therapeutic deci-
sions. Taken together with the results of this study we sug-
est a diagnostic flow as shown in Figure g  2. As both MLPA and routine iFISH have in principle 
comparable detection rates in CLL, MLPA is more cost 
ef-ficient than iFISH and it covers a more broad spectrum 
of target genes  [12], we recommend MLPA to be the 
initial diagnostic test. The impact for the patient car-rying 
rare mutations can be evident: Fabris et al.  [11] reported 
that 2p gain can be present already in early 
 
stages of the disease, particularly in those cases character-
ized by other poor prognostic markers (samples 5, 16 and 
63); del(6q) is generally considered as an intermediate-
risk factor  [1,10] (samples 5 and 68); finally, López et 
al.  [24] reported more rapid disease progression if 
trisomy 12 is accompanied by additional aberrations 
rather than if it is the only genetic abnormality (sample 
62). Also new data may be acquired, as e.g. the impact of 
gain of MYC  [1] (sample 16) or RUNX1 gene  [25] 
(samples 5 and 69) are still unclear in CLL. If the 
diagnostic scheme suggested in Figure  2 would have 
been applied in the 85 patients pre-sented here in 20 of 
them (23.5%) no iFISH would have been necessary. In 
those 20 patients (Tables  6, 7 and  8) MLPA would have 
already identified one or more ad-verse chromosomal 
berrations leading to a therapeutic consequence. a Four patients (Tables  6, 7 and  8) would have been 
grouped into ‘intermediate prognosis’ after MLPA, one of 
them just having a trisomy 12 (sample 37). So in this 
group of pa-tients, only three probes for the adverse 
rognosis regions should be applied in iFISH testing. p Normal MLPA result as found in 29 samples (= ~34%) 
all six (or seven, see legend of Figure  2) FISH probes as 
listed in Figure  2 should be applied to rule out low level 
mosaics of del(11)(q22.3q22.3), +12, del(13)(q14), 
del(17)(p13.1p13.1) or del(14)(q32q32). In the present 
 
T able 7 Regrouping of samples from Table  6 after doing additional i-FISH as suggested in Figure  2 Results according to MLPA Adverse prognosis Intermediate Good prognosis Good prognosis No aberrations
  prognosis “unfavorable” “favorable”  
      
Samples 1+, 2, 3+, 10, 12, 13, 14, 15, 16, 4, 5, 37, 62, 68 20, 21, 22, 23, 25, 26, 27, 6, 7, 8, 9, 11, 31, 36, 57, 70, 71, 72,
 17, 18, 19, 4, 34, 35, 38, 39, 2
54, 58, 60
 28, 29, 30, 43, 44, 45, 46, 32, 33, 40, 41, 73, 74, 75, 76, 77,
 +, 61, 63, 64, 65,  47, 48, 49, 50, 51, 52, 53, 42, 59, 69 78, 79, 80, 81, 82,
   55, 56, 66, 67  83, 84, 85
Number of samples 24 5 25 13 18
per group (absolute)      
Number of samples 28 6 30 15 21
p er group (percent)      
Samples marked with + have rea(14)(q32.33), thus they have to go to the adverse prognosis group. Samples with deletion of 13q14.2 and 13q14.3 
detected by MLPA and/or deletion of 13q14.3 in ≥70% of the nuclei detected by iFISH go to unfavorable subgroup within good prognosis group. Figures 
printed not bold and not in italics are case numbers; figures printed bold and in italics are absolute numbers of samples or same numbers in percent. 
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T able 8 Final result after including result of GTG-banding based on from Tables  6 and  7 Results according to Adverse prognosis Intermediate or Good prognosis Good prog osis n
“favorable” No aberrationsMLPA  unclear prognosis “unfavorable”  
   
6, 7, 8, 9, 11, 3  Samples 1, 2, 3, 10, 12, 13, 14, 15, 16, 4, 5, 36*, 37, 62, 68 20, 21, 22, 23, 25, 26, 27, 28, 1, 71, 72, 73, 74, 75, 76,
 17, 18, 19, 24, 34, 35, 38, 39,  29, 30, 43, 44, 45, 46, 47, 48, 32, 33, 40, 41, 77, 78, 79, 80, 81, 82,
 54, 57*, 58, 60, 61, 63, 64, 65, 70*  49, 50, 51, 52, 53, 55, 56, 66, 67 42, 59, 69 83, 84, 85
Number of samples 26 6 25 13 15 
per group (absolute)      
Number of samples 
er group (percent) 31 7 30 15 17 p      
Samples marked with * have additional aberration not detectable by MLPA or routine iFISH. Figures printed not bold and not in italics are case numbers; 
figures printed bold and in italics are absolute numbers of samples or same numbers in percent. 
 
cohort e.g. samples 2 and 13 go to “good prognosis”, 
samples 3 and 60 to “adverse prognosis” and sample 4 to 
intermediate prognosis” group (Tables “  6, 7 and  8). Finally, 32 patients (Tables  6, 7 and  8) have been classi-
fied as ‘good prognosis’ after MLPA. Here, the same FISH 
probes as for normal MLPA result should be used for further 
subclassification (Figure  2). Again patients then may have to 
be moved to other prognostic groups if additional or low 
level mosaics are identified. Also it is known that CLL cases 
with del(13)(q14.2q14.2) go into unfavorable subgroup, as 
do such cases with biallelic dele-tions in 13q14. Finally, 
del(13)(q14.3q14.3) detected in ≥70% of the cells are also an 
indication to group a patient in unfavorable subgroup of 
‘good prognosis’ group  [1,22]. Thus, further I-FISH studies 
are necessary also for patients with del(13)(q14.2q14.2) 
nd/or del(13)(q14.3q14.3) in MLPA. a In case only MLPA and iFISH would have been done in 
the presently studied 85 patient still 3 samples would have 
been misclassified. Thus we suggest in Figure  2 still 
GTG-banding as the initial test for CLL diagnostics. 
Compared to a flow just applying banding cytogenetics 
and routine iFISH for diagnostics of CLL the introduction 
of the flow from Figure  2 would apply only 344 instead 
of 425 FISH-probes, i.e. 20% less.  
C onclusion The present study shows the importance of combining 
cytogenetics, molecular genetics and molecular cyto-
genetics to achieve a comprehensive characterization of 
acquired genetic alterations being present in CLL.  
M ethods P atients and sample preparation The present study included 85 samples of patients suffer-
ing from CLL (Additional file  1: Table S1 and Additional 
file  2: Table S2) diagnosed according to standard criteria  
[26]. The samples were obtained under informed consent 
of the corresponding patients and according to institu-
tional ethical committee guidelines (Ethical commitee of 
he Friedrich Schiller University Jena). t DNA from lymphocytes was extracted by a commer-
cial kit (Qiagen, Hilden, Germany) and was derived from 
 
different sources: 2 samples from heparinized bone mar-
row, 8 samples from heparinized blood, and 75 samples 
from cytogenetically prepared cells fixed in methanol/ 
acetic acid (3:1) – 48 of them derived from bone marrow 
and 27 from blood (Additional file  1: Table S1). 
 
G TG-banding and FISH analysis The blood or bone marrow samples were stimulated with 
phorbol ester, i.e. 12-O-tetradecanoylphorbol-13-acetate 
(TPA) and cultivated for 96 hours, and a standard cyto-
genetic cell preparation following air drying method was 
done  [27]. GTG-banding and iFISH analyses were rou-
tinely done in each sample following standard procedures  
[27,28]. In 67 samples chromosomes could be obtained 
rom the material prepared. f For routine iFISH the following commercially available 
probe sets (Abbott/Vysis, Wiesbaden, Germany) were used: 
LSI p53/LSI ATM (in 17p13.1 and 11q22.3), LSI D13S319/ 
LSI 13q34/CEP 12 (in 13q14.3, 13q34 and 12p11.1-q11.1), 
nd LSI IGH dual color, break-apart probe (in 14q32.33). a Additionally, the following probes were used to validate 
and possibly confirm the results of MLPA: 
 
– from Abbott/Vysis (Wiesbaden, Germany): LSI 13 
(RB1 in 13q14.2), CEP 6 (D6Z1 in 6p11.1-
q11,1), CEP 17 (D17Z1 in 17p11.1-q11.1) and 
CEP 18 (D18Z1 in 18p11.1-q11.1);   – from Zytovision (Bremerhaven, Germany): 
ZytoLight ®SPEC ALK Dual Color Break Apart   (in 2p22.32 ~ 22.31), ZytoLight ®SPEC NMYC/2q11 
Dual Color (in 2q24.3 and 2q11), ZytoLight ®SPEC 
MYB Dual Color Break Apart (in 6q23.3), ZytoLight 
®SPEC ESR1/CEN 6 Dual Color (in 6q25.1 and 
6p11.1-q11.1), ZytoLight ®SPEC CMYC/CEN 8 Dual 
Color (8q24.21 and 8p11.1-q11.1), ZytoLight ®SPEC 
ETV6/RUNX1 Dual Color Dual Fusion (in 12p13.2 
and 21q22.12); and   – BACPAC Resources Center (Oakland, USA): RP1-
142 L7 in 6q21 (gene FYN), RP11-318A15 in 
17q25.1 (gene UNC13D), RP11-346H17 in 18q21.2 
(gene DCC), RP11-37D8 in 6q27 (gene SMOC2) 
and RP11-411B in 18p11.22 (gene RNMT).  
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Table 9 Loci addressed in the commercially available 
LPA kit used in this study M Targets Loci Number of probes included in kit
   
MYCN 2p24.3 2 
ALK 2p23.2 ~ 23.1 1 
MIR145 5q33.1 1 
EBF1 5q33.3 2 
MIR146A 5q33.3 1 
FYN 6q21 1 
MYB 6q23.3 1 
ESR1 6q25.1 1 
SMOC2 6q27 1 
IKZF1 7p12.2 3 
CDK6 7q21.2 1 
RELN 7q22.1 1 
MET 7q31.2 1 
DPP6 7q36.2 1 
MYC 8q24.21 2 
MTAP 9p21.3 1 
CDKN2A 9p21.3 1 
CDKN2B 9p21.3 1 
PAX5 9p13.2 2 
PTEN 9p13.1 1 
PTEN 10q23.31 1 
ATM 11q22.3 4 
ETV6 12p13.2 2 
MDM2 12q15 1 
CCND2 12p13.32 1 
RB1 13q14.2 2 
MIR15A 13q14.3 1 
DLEU1 13q14.3 1 
DLEU2 13q14.3 1 
TP53 17p13.1 4 
UNC13D 17q25.1 1 
IKZF3 17q12 1 
DCC 18q21.2 1 
RNMT 18q21.2 1 
CACNA1A 19p13.13 1 
CHMP2A 19q13.43 1 
RUNX1 21q22.12 2 
    
For each iFISH analysis, at least 100–200 interphase 
nuclei were examined per sample and FISH-probe. 
 
M LPA analysis MLPA was performed using SALSA MLPA probemix P377-
A1 for Hematological Malignancies Kit from (MRC-
Holland, Amsterdam, The Netherlands). The P377-A1 
probemix kit contains probes for 37 genes covered by overall 
52 probes, which have diagnostic or prognostic significant 
role in hematologic malignancies (see Table  9). 
   
 
MLPA was performed according to the manufacturer’s 
protocol, which includes three reaction phases: hybridization, 
ligation, and PCR. Finally, a capillary electrophoresis was 
used to separate and analyze MLPA PCR products. 
Genemarker software was used to analyze the peak areas of 
the MLPA PCR products, and the ratio was normalized to a 
healthy control. Threshold of detection was set at 0.65-1.35, 
to minimize the false positive cases.  
Additional files 
 
 Additional file 1: Table S1. Gender, age and cytogenetic results 
of the studied cases/samples.   Additional file 2: Table S2. Aberrations detected in 85 CLL samples 
and by which method the corresponding aberrations could be detected. 
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The translocation t(8; 21)(q22;q22)/RUNX1/RUNX1T1
is one of the most common translocations in pediatric 
acute myeloid leukemia (AML), accounting for 10–20% of 
all cases [1]. At the molecular genetic level, the rearrange-
ment is defined by involvement of the RUNX1 (AML1)
gene on chromosome 21q22 and the RUNX1T1 (ETO)
gene on chromosome 8q22, resulting in the RUNX1/
RUNX1T1 (AML1/ETO) fusion gene product [2]. The fu-
sion protein disrupts the core binding factor transcription 
complex, leading to abnormalities in cell differentiation, 
proliferation and apoptosis. It is also thought that the fu-
sion product is a driver of myeloid leukemogenesis in this 
AML subtype [3].
Approximately 3–4% of cases of AML with the t(8; 21) 
(q22;q22) occur in the context of complex rearrange-
ments. Although t(8; 21) is associated with a good prog-
nosis, the impact of the complex t(8; 21) variants is con-
troversial. Some researchers have reported a favorable 
outcome for AML patients with complex t(8; 21) variants, 
while others have not confirmed these observations [4];
in these series, almost all of the patients were adults [2, 
4, 5]. The clinical relevance and implications of t(8; 21) 
variants in pediatric patients are yet to be determined. 
These translocations are rare, so there is limited 
informa-tion on their prognostic impact. Thus, to make a 
contri-bution to the registry of t(8; 21) with complex 
variants, we present a case that belongs to this rare 
subgroup. We report on a child with AML harboring a 
novel three-way cryptic variant t(8; 13; 21), as revealed 
by detailed molecu-lar studies.
From May 2007 to March 2014, we analyzed samples 
from 114 children and adolescents (aged 0–18 years) with 
AML, 13 (11.4%) of whom harbored the t(8; 21) (q22;q22) 
and were examined by means of GTG band-ing, 
fluorescence in situ hybridization (FISH) and RT-PCR. Of 
these 13 RUNX1/RUNX1T1-positive patients, 3 (2.6%) did 
not have classic t(8; 21) by conventional karyo-typing. 
When FISH assay was performed, it was possible to 
observe that there was a third chromosome involved, with 
a RUNX1/RUNX1T1 split signal, thus characterizing
© 2015 S. Karger AG, Basel Maria Luiza Macedo Silva, PhD
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Fig. 1. a Partial G-banding karyotype. The red 
arrow shows a missing portion in chro-
mosome 8, and the green arrow shows a 
gain of chromosomal material on chromo-
some 13. b FISH with the AML1/ETO dual-
color, dual-fusion probe, showing the 
RUNX1/RUNX1T1 fusion on derivative
chromosome 8 and a RUNX1T1 split sig-nal 
to chromosome 13. c Complementary FISH, 
with a subtelomeric probe for the 13qter 
region, revealing that a portion of this region 
was translocated to chromo-some 21. d FISH 
with whole-chromosome painting (wcp) 
probes and MCB for chro-mosomes 8, 13 
and 21, showing the origin and the 
breakpoints of each rearrange-ment. e RT-
PCR confirmed the presence of the 
RUNX1/RUNX1T1 fusion and revealed a 
PCR product of 260 base pairs (bp).
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a masked variant of t(8; 21). These 3 cases were 
then se-lected to be studied by means of 
multicolor chromosome banding (MCB). We 
describe a novel t(8; 13; 21) variant in detail.
A 13-year-old girl was admitted with a 5-month his-tory 
of pallor and upper-airway symptoms associated with 
persistent fever, otalgia and dysacousia. At admis-sion, 
she had a white blood cell count of 22 × 109/l, a plate-let
count of 96 × 109/l and hemoglobin of 6.2 g/dl. A chest X-
ray showed consolidation in the lower/upper/left/right 
lobes, consistent with bacterial pneumonia. Physical ex-
amination revealed lymphadenopathy in the cervical and 
inguinal regions, hepatomegaly (4 cm) and splenomegaly 
(7 cm). The bone marrow was hypercellular with 64% 
myeloid blast cells positive for CD45, CD34, CD117, MPO, 
CD33, CD13, HLA-DR, CD123, CD15 and CD19, i.e. 
compatible with AML.
GTG banding analysis defined the karyotype as 45,X,-
X,del(8)(q22),der(13q3?) in 23 metaphases (fig. 1a). FISH 
analysis confirmed a cryptic fusion RUNX1/ RUNX1T1 on 
derivative chromosome 8, with the pres-ence of a 
RUNX1T1 split signal on derivative chromo-some 13 (fig. 
1b). Complementary FISH analysis using a subtelomeric 
probe for the 13q region, showed a 13qter minor signal on 
chromosome 21 characterizing a cryptic translocation (fig. 
1c). The application of whole-chro-mosome painting 
probes for chromosomes 8, 13 and 21 revealed a three-
way translocation. To characterize the
breakpoints of this complex rearrangement, MCB 
stud-ies were applied revealing the karyotype: 
45,X,-X,t(8; 13; 21)(q22;q33;q22) (fig. 1d). RT-
PCR for the RUNX1/ RUNX1T1 fusion revealed a 
product of 260 base pairs (fig.1e).
The patient was stratified as being at standard risk, 
and was treated according to the AML-BFM-2004 
protocol [6]. She achieved complete remission, but after 
receiving an intensification block, she developed febrile 
neutrope-nia and sepsis. She died of cardiac and 
respiratory failure 5 months after the initial diagnosis.
There are at least two steps for the formation 
mech-anism of the complex t(8; 21), following the 
formation of standard t(8; 21)(q22;q22) and the 
RUNX1/RUNX1T1 fusion gene [7]. Material from the 
distal long arm of chromosome 21q22 translocates to 
the long arm of chromosome 8, but the end of 
chromosome 8 translo-cates to a third chromosome. 
The remainder of the third chromosome translocates 
to chromosome 21. The same behavior may have 
occurred in the transloca-tion in our patient and in 2 
others previously reported [7, 8].
The involvement of chromosome 13 in a complex t(8; 
21) variant has, so far, been reported in 3 patients [7, 8]
including ours. In contrast to the other cases, the variant 
t(8; 13; 21)(q22;q33;q22) described here presented as a 
masked karyotype on GTG banding, and additional ma-
terial was cryptically translocated on derivative chromo-
Acta Haematol 2015;134:243–245 CapeladeMatos/DeFigueiredo/Liehr/
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some 21, thus adding a novel t(8; 13; 21) variant to the lit-
erature.
Although the t(8; 21) complex variant accounts for only 
0.05–1.1% of cases of childhood AML [2, 4, 5, 9], its 
frequency was higher (approx. 2.6%) in our cohort, sug-
gesting that, in pediatric AML, a detailed characterization 
of RUNX1T1 split signal via a combination of FISH, MCB 
and RT-PCR approaches may be necessary to uncover 
such complex variants. In our cohort as well as in the pre-
viously described cases [7, 8], the RUNX1T1 gene (8q22) 
often splits to the third chromosome involved in the 
translocation. Thus, the observation that a similar forma-
tion mechanism of the complex t(8; 21) variant that pref-
erentially involves the same chromosome regions, along 
with the higher frequency of complex t(8; 21) variants (that 
we observed in our cohort), reinforces the impor-tance of 
the clarification of such complex cases in order to 
investigate if the genes in these regions are involved in 
leukemogenesis.
Furthermore, it is important that cases with complex 
conventional karyotypes and a RUNX1/RUNX1T1 split 
signal involving ≥3 chromosomes are analyzed by a com-
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Abstract. Deletions within chromosome 11q22-23, are consid- 
ered among the most common chromosomal aberrations in 
chronic lymphocytic leukemia (CLL), and are associated 
with a poor outcome. In addition to the ataxia telangiectasia 
mutated (ATM) gene, the baculoviral IAP repeat-containing 3 
(BIRC3) gene is also located in the region. BIRC3 encodes 
a negative regulator of the non-canonical nuclear factor 
κ-light-chain-enhancer of activated B cells (NF-κB) protein. 
Disruption of BIRC3 is known to be restricted to CLL luda- 
rabine-refractory patients. The aim of the present study was 
to determine the frequency of copy number changes of BIRC3 
and to assess its association with two known predictors of nega- 
tive CLL outcome, ATM and tumor protein 53 (TP53) deletions. 
To evaluate the speciicity of BIRC3 alterations to CLL, BIRC3 
copy numbers were assessed in 117 CLL patients in addition 
to 45 B-cell acute lymphocytic leukemia (B-ALL) patients. 
A commercially available multiplex ligation dependent probe 
ampliication kit, which includes four probes for the detection 
of TP53 and four probes for ATM gene region, was applied. 
Interphase฀directed luorescence in situ hybridization was used 
to apply commercially available probes for BIRC3, ATM and 
TP53. High resolution array-comparative genomic hybridiza- 
tion was conducted in selected cases. Genetic abnormalities of 
BIRC3 were detected in 23/117 (~20%) of CLL and 2/45 (~4%) 
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of B-ALL cases. Overall, 20 patients with CLL and 1 with  
B-ALL possessed a BIRC3 deletion, whilst 3 patients with CLL  
and 1 with B-ALL harbored a BIRC3 duplication. All patients  
with an ATM deletion also possessed a BIRC3 deletion. Only     
CLL cases possessed deletions in BIRC3, ATM and TP53  
simultaneously. Evidently, the deletion or duplication of BIRC3  
may be observed rarely in B-ALL patients. BIRC3 duplication  
may occur in CLL patients, for which the prognosis requires  
additional studies in the future. The likelihood that TP53  
deletions occur simultaneously with BIRC3 and/or ATM aber-  
rations is low. However, as ATM deletions may, but not always,  
associate with BIRC3 deletions, each region should be consid-  
ered in the future diagnostics of CLL in order to aid treatment  
decisions, notably whether to treat with or without ludarabine.     
 
Introduction  
 
Chronic lymphocytic leukemia (CLL) is the most common type     
of leukemia observed in people aged >50 years in Western coun-     
tries. CLL is characterized by a heterogeneous clinical course,     
with a time to progression ranging from months to decades (1).     
The presence of cytogenetic abnormalities is a hallmark of     
CLL. The most common recurrent aberrations in CLL affect    
chromosomes 11q, 13q, 14q, 17p and the whole of chromo-   
some 12. Certain abnormalities, including deletions in 11q22.3,   
the ataxia telangiectasia mutated (ATM) gene (10-20%), and   
17p13.1, the tumor protein 53 (TP53) gene (5-10%), are associ-     
ated with a poor clinical outcome. Therefore, the detection of     
these aberrations is important for identifying high-risk patients,     
who suffer from rapid disease progression and a decreased     
overall survival time (2). Other frequent chromosomal aberra-     
tions in CLL are associated with a good (deletions in 13q14 or     
14q32.33) or intermediate (trisomy 12) prognosis (1,3-5).  
CLL is considered to be an insidious disease. Certain  
CLL patients, particularly patients with a good prognosis,     
survive for several years without requiring treatment; however,  
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 another subgroup of patients experience an aggressive disease inhibitor or and alemtuzumab/corticosteroids (8,13). BIRC3  
 course and have a short life expectancy, despite aggressive abnormalities provide a molecular rationale for using NF-κB  
 treatment (6). The latter group tends to exhibit a particular lack inhibitors, which remain under development (7).  
 of response to ludarabine฀based regimens, which are gener-  
 ally considered to be the irst line of treatment for CLL (6). Materials and methods  
 In a large fraction of these patients, the molecular basis of the  
 aggressive clinical course remains unclear; however, in ~40% Patients and sample preparation. The present study included  
 of patients, the molecular basis is hypothesized to be due to 117 CLL patients, and 45 B-cell acute lymphocytic leukemia  
 TP53 disruption. In addition, the activation of the nuclear (B-ALL) patients that were diagnosed according to standard  
 factor κ-light-chain-enhancer of activated B cells (NF-κB) criteria (14). The samples were obtained with the informed  
 pathway is considered to be a mechanism of resistance to consent from the corresponding patients and according to the  
 disease eradication (7). institutional Ethical Committee guidelines. For CLL cases,  
 From a clinical perspective, CLL cases may be divided DNA was extracted from lymphocytes using a commercial kit  
 into three major clinical phases: i) Newly diagnosed CLL; (Qiagen, Hilden, Germany), according to the manufacturer's  
 ii) progressive CLL; and iii) relapsed or ludarabine฀refractory protocol. For B-ALL cases, DNA was derived from cytoge-  
 CLL. TP53 abnormalities are observed in 40-50% of relapsed netically prepared cells, which were ixed in methanol/acetic  
 and fludarabine-refractory CLL cases and the deletion of acid (dilution, 3:1) (Table I).  
 11q22-23 occurs in 25-30% of relapsed or ludarabine฀refractory  
 CLL patients (8). In a large previous study, 637 patients were Interphase luorescence in situ hybridization (iFISH) analysis.  
 classified into four risk groups according to a multivariate iFISH analyses were performed as previously described (2),  
 analysis of overall survival, which was based on genomic using the following commercially available probes: LSI  
 abnormalities and the mutational status of TP53, baculoviral p53/LSI ATM (in 17p13.1 and 11q22.3), CEP 3 (D3Z1 in  
 IAP repeat-containing 3 (BIRC3), translocation-associated 3p11.1-q11.1), CEP 4 (D4Z1 in 4p11-q11), CEP 7 (D7Z1 in  
 notch homolog 1 and splicing factor 3B subunit 1. Notably, 7p11.1-q11.1), CEP 11 (D11Z1 in 11p11.11-q11), CEP 16 (D16Z2  
 the high-risk group was composed of patients that exhibited in 16p11.1-q11.1), CEP 17 (D17Z1 in 17p11.1-q11.1) and CEP 18  
 disruption to TP53 and/or BIRC3 (9). (D18Z1 in 18p11.1-q11.1), all from Vysis (Abbott GmbH &  
 The  BIRC3  gene  is  located  on  11q22.2, is ~6 Mb Company, KG, Wiesbaden, Germany); and ZytoLight® SPEC  
 centromeric to the ATM gene locus and is considered to be BIRC3/MALT1 DualColor Dual Fusion probe (in 11q22.2 and  
 a negative regulator of the non-canonical NF-κB signaling 18q21.32) from ZytoVision GmbH (Bremerhafen, Germany).  
 pathway (10,11). BIRC3 cooperates with tumor necrosis For each iFISH analysis, 100-200 interphase nuclei were  
 factor receptor-associated factors 2 and 3, in the same protein examined per patient and probe.  
 complex that negatively regulates the mitogen-activated  
 protein kinase 14, a serine-threonine kinase and central Multiplex ligationdependent probe ampliication (MLPA)  
 activator of non-canonical NF-κB signaling (7). In addi- analysis. MLPA was performed using the SALSA MLPA  
 tion, a frequent aberration associated with BIRC3 is the probemix P377-A1 for Hematological Malignancies kit  
 recurrent t(11;18)(q21;q21) translocation, which involves the (MRC-Holland, Amsterdam, Netherlands). The P377-A1  
 mucosa-associated lymphoid tissue lymphoma translocation probemix kit contains 52 probes for 37 genes. The TP53  
 gene 1 (MALT1), located on 18q21.32. This type of altera- and ATM genes were assessed by four probes each; however,  
 tion appears in mucosa-associated lymphoid tissue (MALT) probes for the BIRC3 gene were not included in the kit (2).  
 lymphoma (12). MLPA was successfully performed on 85/117 CLL samples  
 In CLL, deletions within the long arm of chromosome 11 and 32/45 B-ALL samples. MLPA was not successful for the  
 may be highly variable in size. The deletion may be distin- remaining samples due to fragmentation of DNA.  
 guished as the more common ‘classical or large deletion’ or  
 an ‘atypical or small deletion’, which are uncommon and Array-comparative genomic hybridization (aCGH). aCGH  
 more frequently associated with ATM mutations. This varia- was performed using the Agilent SurePrint G3 Human  
 tion indicates that other genes may possibly contribute to the Genome Microarray 180 K (Agilent Technologies, Santa  
 pathobiology of 11q deletions in CLL, and one of the genes Clara, CA, USA), as previously described (15). aCGH was  
 that is hypothesized to be involved is BIRC3 (13). BIRC3 applied in 3 CLL patients that possessed a BIRC3 duplication  
 disruption, mutations or deletions are rarely detected in and in 1 B-ALL patient that possessed a BIRC3 deletion.  
 CLL at diagnosis (4% of patients), but are detected in 24%  
 of ludarabine฀refractory CLL patients. In a previous study, Results  
 ludarabine฀sensitive patients did not exhibit BIRC3 mutations  
 initially, which suggests that BIRC3 disruption may be specii- Gene copy numbers. BIRC3 gene copy number variations  
 cally associated with a chemo-refractory CLL subtype (7). were detected in 23/117 (~20%) of CLL and 2/45 (~4%) of  
 Therefore, BIRC3 disruption may be added to the panel of B-ALL cases, as summarized and detailed in Fig. 1. BIRC3  
 cytogenetic abnormalities, as the abnormality may be helpful in deletions were identiied in 20 cases of CLL (cases C฀1 to  
 the early identiication of relapsed and ludarabine฀refractory C-20) and in 1 case of B-ALL (case A-1). ATM deletion  
 CLL patients. Affected patients should be considered for other was detected in the identical 20 CLL and 1 B-ALL cases.  
 treatment regimens, including cyclin-dependent kinase inhib- Therefore, all patients with a BIRC3 deletion also possessed  
 itor, Bruton's tyrosine-kinase inhibitor, B-cell lymphoma 2 an ATM deletion. However, in cases C-1, C-8, C-10, C-13 and  
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 Table I. Gender, age and cytogenetic results of the B-ALL and CLL cases used in the present study. 
 
 Case no. Gender Age, years DNA extracted from Cytogenetic results 
 
  
 A-1 Male 84 BM 46,XY,-9,t(9;22)(q34;q11),del(11)(q),+mar[cp3]/46,XY[5]        A-2 Male 23 BM Hyperdiploid/46,XY 
       A-3 Male 34 BM 46,XY 
       A-4 Male 19 BM 46,XY 
 A-5 Female 76 BM 45,X,-X[14]/46,XX[2] 
 C-1 Male 73 BM 46-47,XY,del(11)(q22q2?3),add(17)t(17;?)(p11.2;?)[cp5]/ 
 45-46,XY,del(11)(q22q2?3),del(17)(p11.2)[cp4]/ 
 43-46,XY,del(11)(q22q2?3)[cp2]/ 
 46,XY[7] 
 C-2 Female 50 B n.a.  C-3 Female 39 BM 43-46,XY,del(11)(q2?2q2?4)[cp5]/  45-46,XY,del(11)(q2?2q2?4),del(15)(q1?1q2?3)[cp11]/  46,XY[1] 
        C-4 Male 64 BM 46,XY 
        C-5 Male 43 BM 46,XY  
 C-6 Male 67 BM 46,XY 
 C-7 Male 77 BM 46,XY,del(11)(q?21),add(20)(p13)[7]/ 
 45,X,-Y[10]/ 46,XY[3]         C-8 Male 53 BM 46,XY 
        C-9 Male 59 BM n.a. 
 C-10 Male 73 BM 45,XY,der(2)t(2;13)(q?37;q?14),?del(6)(p?23), 
 del(11)(q?21)der(12)t(12;13)(q?24;q?22),-13[cp4]/ 
 46,XY[19] 
 C-11 Male 72 B n.a. 
 C-12 Female 73 BM 46,XX,add(11)(q?22)[3]/ 46,XX[12] 
        C-13 Male 54 B 46,XY 
        C-14 Male 68 BM 46,XY 
        C-15 Male 53 BM 46,XY 
        C-16 Male 75 BM n.a.  
 C-17 Female 67 BM 46,XX[18] 
 45,X,-X[1]         C-18 Male 74 BM n.a. 
        C-19 Male 65 BM 46,XY 
 C-20 Male 77 B 45-46,XY,del(11)(q?22q?23)[cp14] 
 46,XY[5] 
 C-21 Male 83 BM 47,XY,-11,+12,+mar[cp3]/ 
 47,XY,del(5)(p1?3),-11,+12,-17,+mar1,+mar2[cp6]/ 
 46,XY[9] 
        C-22 Male 72 BM 46,XY 
        C-23 Male 59 B 46,XY 
        C-24 Female 66 B n.a. 
        C-25 Female 71 B 46,XX  C-26 Male 65 BM 46,XY,?t(3;?)(p21;?),add(17)(p?12)ort(17;?),-8,+mar[cp7]  46,XY[9]  C-27 Female 74 B 46,XX  C-28 Female 74 BM 46,XX,i(17)(q10)[1]/ 46,XX,+12,i(17)(q10),-21[9]/  46,XX,t(3;?)(q2?9;?)[4],-7[4],+12[4],i(17)(q10)[4][cp4]/  46,XX[4]  
        C-29 Female 90 B n.a. 
        C-30 Male 56 BM n.a. 
        C-31 Female 65 BM 46,XX 
 
  
 A-, B-ALL case; C-, CLL case; BM, cell pellet in Carnoys fixative from bone marrow; n.a., data not available.  
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 Table II. Summary of MLPA and iFISH results of TP53, ATM, BIRC3 and MALT1 in all studied cases. 
 
 TP53 (%) ATM (%) BIRC3 (%) MALT1 (%) 
 ------------------------------------------------- -------------------------------------------------- 
 Case no. MLPA iFISH MLPA iFISH iFISH iFISH  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        C-32 to C-91 N N N N N N 
        C-92 to C-117 n.a. N n.a. N N N 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
           Data are expressed as type of change to copy number (% of cells with aberration). TP53, tumor protein 53; ATM, ataxia telangiectasia mutated;  
BIRC3, baculoviral IAP repeat-containing 3; MALT1, mucosa-associated lymphoid tissue lymphoma translocation gene 1; MLPA, multiplex 
          ligation-dependent probe ampliication; iFISH, interphase luorescence in situ hybridization; A-, B-ALL case; C-, CLL case; N, no aberration;  
         D, deletion; A, ampliication; n.a., data not available.  
   
 
 
        C-20 the detected clone sizes with deletions in BIRC3 and 
        ATM were extremely varied from one another. In case C-1, 
        the clone with the ATM deletion was 8x smaller compared 
 
 
C-10, C-13 and C-20, the clone with the BIRC3 deletion  
was 2-3x smaller than that with the ATM deletion. A BIRC3  
duplication was identiied in 1 case of B-ALL (case A-2) and  
        with that with the BIRC3 deletion, whereas in cases C-8, in 3 CLL patients (cases C21 to C23) (Table II).  
A-1 N N D D (76.5) D (75.0) N 
A-2 n.a. A (100.0) n.a. A (100.0) A (100.0) A (100.0)
A-3 D D (8.5) N N N N
A-4 D D (10.0) N N N N
A-5 D D (10.0) N N N N
A-6 to A-33 N N N N N N
A-34 to A-45 n.a. N n.a. N N N
C-1 D D (86.0) D D (11.0) D (80.0) N
C-2 D D (21.0) N D (23.0) D (22.0) N
C-3 N N D D (98.0) D (90.0) N
C-4 N N D D (23.5) D (30.0) N
C-5 N N D D (24.0) D (25.0) N
C-6 N N D D (88.0) D (85.0) N
C-7 N N D D (90.0) D (80.0) N
C-8 N N D D (77.0) D (50.0) N
C-9 N N D D (98.0) D (75.0) N
C-10 N N D D (87.0) D (60.0) N
C-11 N N D D (95.0) D (90.0) N
C-12 N N D D (83.0) D (80.0) N
C-13 N N D D (93.0) D (25.0) N
C-14 N N N D (33.0) D (15.0) N
C-15 N N N D (12.0) D (13.0) N
C-16 n.a. N n.a. D (80.0) D (78.0) N
C-17 n.a. N n.a. D (10.0) D (9.0) N
C-18 n.a. N n.a. D (73.0) D (64.0) N
C-19 n.a. N n.a. D (9.0) D (10.0) N
C-20 n.a. N n.a. D (96.0) D (42.0) N
C-21 D D (16.0) N A (50.0) A (50.0) A (50.0)
C-22 D D (40.0) N A (40.0) A (40.0) A (40.0)
C-23 N N N N A (36.0) N
C-24 D D (19.0) N N N N
C-25 D D (36.0) N N N N
C-26 D D (89.0) N N N N
C-27 D D (77.0) N N N N
C-28 D D (95.0) N N N N
C-29 N D (11.5) N N N N
C-30 n.a. D (86.5) n.a. N N N
C-31 N N N N N A (75.0)
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Figure 1. The distribution and of BIRC3, ATM and TP53 aberrations in CLL and B-ALL patients are summarized. (A) In CLL and B-ALL, the majority of 
           patients did not show alterations in the three genes. Distribution of the loss and gain of copy numbers in the two patient groups is depicted. (B) Combinations of  
          loss and gain of the three genes were identiied in the patients with CLL and B฀ALL, with alterations from part (A). BIRC3, baculoviral IAP repeat-containing 3;  
          ATM, ataxia telangiectasia mutated; TP53, tumor protein 53; CLL, chronic lymphocytic leukemia; B-ALL, B-cell acute lymphocytic leukemia.  
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           Figure 2. (A) Array comparative genomic hybridization conirmed the deletion in TP53, which was detected initially using iFISH and multiplex ligation dependent   
           probe ampliication for CLL cases C-21 and C-22. The whole short arm was deleted and the long arm was possibly duplicated due to an isochromosome 17a  
           formation, at least in case C-21. (B) Examples for gain of copy numbers for BIRC3 and MALT1 in the 2 cases by iFISH: i) C-21, an example of 3 copies and ii) C-22,   
an example of 4 copies. (C) iFISH results of the CLL case C-23. BIRC3 had 3 copies in certain cells; however ATM, MALT1 and TP53 exhibited only 2 copies 
           each, in all cells. TP53, tumor protein 53; CLL, chronic lymphocytic leukemia; iFISH, interphase fluorescence in situ hybridization; BIRC3, baculoviral IAP   
           repeat-containing 3; MALT1, mucosa-associated lymphoid tissue lymphoma translocation gene 1; ATM, ataxia telangiectasia mutated. 
 
 
 
 
 
        With regard to TP53 abnormalities, 3 patients with B-ALL 
        possessed a TP53 deletion in the absence of any aberrations 
        in BIRC3. TP53 deletions were present in 11 CLL patients, 
        7 of which possessed no associated BIRC3 aberrations and, 
         notably, 2 of which were accompanied by BIRC3 and ATM 
in addition to TP53 deletion. To study these cases in greater  
depth, iFISH was performed using the centromeres of chro-  
mosomes (CEP) 3, 4, 7, 11, 16 and 18. For these chromosomes,  
3 signals were detected in 11% (case C-21) and 25% (case  
C-22) of the cells, and 4 signals were detected in 29% (case  
 ampliication. C-21) and 25% (C-22) of the cells, respectively (Fig. 2).  
 
        BIRC3 duplication. In total, 3 CLL patients harbored a 
        BIRC3 duplication (cases C-21 to C-23), 2 of which (C-21 and 
The third CLL case (C-23) with BIRC3 duplication was  
associated with normal copy numbers of TP53 and ATM; the  
centromeric probes for chromosomes 11 and 17 only revealed  
        C-22) were accompanied by ATM and MALT1 duplications 2 signals each (Fig. 2).  
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          Figure 3. Results obtained for B-ALL case A-1 by array comparative genomic hybridization and iFISH are summarized. (A) Deletion in 11q22-q23, initially  
          detected by iFISH, resulted in loss of the whole long arm of a chromosome 11. (B) Examples for heterozygote deletions of ATM and BIRC3 detected by iFISH  
         are depicted. iFISH, interphase luorescence in situ hybridization; ATM, ataxia telangiectasia mutated; BIRC3, baculoviral IAP repeat-containing 3; MALT1,  
          mucosa-associated lymphoid tissue lymphoma translocation gene 1; D11Z1, CEP 11 probe.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Discussion 
 
       The present study regarding BIRC3 copy number variations 
       in 117 CLL and 45 B-ALL patients has revealed several 
       major findings that, to the best of our knowledge, have not 
       been previously reported. Firstly, BIRC3 duplications were 
       detected in 3 cases of CLL, and 2 of these were associated 
       with ATM and MALT1 duplications, in addition to TP53 
       deletions; BIRC3 amplification was not more than a hint 
        on a hyperdiploid cell clone as reported in CLL earlier, but 
        not as a frequent event (16,17). In addition, 1 B-ALL patient 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The disruption of BIRC3 is specifically restricted to  
chemo-refractory cases in progressive CLL patients, and may  
selectively associate with fludarabine-refractory patients  
with normal TP53 (7). Therefore, another notable inding of  
the present study is that BIRC3 abnormalities were associ-  
ated with TP53 deletion in only 4/117 CLL cases. According   
to previous studies, the frequency of BIRC3 disruption is low   
at diagnosis; however, BIRC3 disruptions tend to accumu-  
late among refractory CLL and emerge over time. Patients  
harboring a BIRC3 disruption typically experience an  
aggressive disease course, even compared with other clini-  
cally aggressive groups (11,24). This aspect of the disease  
      
 Based on the aCGH results for cases C-21, C-22 and C-23, possessed a duplication of BIRC3 due to partial hyperdiploidy,  
 the TP53 deletion in C฀21 and C฀22 was conirmed; however, which is more common in B-ALL compared with CLL, and  
 BIRC3 was normal in all 3 patients (Fig. 2). Therefore, is associated with good prognosis in pediatric patients (18). A  
 cases C-21 and C-22 had a mixture of a malignant triploid CLL-case with a BIRC3 duplication possessed normal ATM  
 and tetraploid cell clones and a deletion in TP53. Case C-23 and TP53 copy numbers; however, the duplication was not  
 demonstrated the selective gain of copy numbers for BIRC3, detected by aCGH, most likely due to the low sensitivity of  
 without ATM involvement, in 36% of the cells; however, this aCGH for mosaic detection, despite being present in 36% of  
 inding was not detectable using aCGH. the cells. Previous studies on the interaction of BIRC3 with  
   the NF-κB pathway indicate that BIRC3 duplication may lead  
 MALT1 duplication. The patient with a MALT1 duplication to the inactivation of tumor suppressor activity (19-21).  
 (case C-31) possessed a trisomy of chromosome 18, which As the predominant morphological feature of CLL  
 was confirmed using MLPA and iFISH. The probes for is the accumulation of small B lymphocytes (1), B-ALL  
 the deleted in colorectal cancer gene on 18q21.2 and RNA patients were chosen to be the second group to be tested for  
 (guanine-7-)methyltransferase gene on 18p11.22 revealed a BIRC3-alterations in the present study. Therefore the second  
 duplication by MLPA, which was conirmed by iFISH in 75% important inding of the present study is the detection of  
 of the cells. a BIRC3 deletion in 1 of the 45 studied B-ALL cases. The  
   aCGH for case A-1 revealed the deletion of almost all of the  
 BALL patients. Regarding B-ALL patients, 1 case revealed long arm of chromosome 11, and the most frequent aberra-  
 a deletion in BIRC3 along with ATM (case A-1), and another tions associated with chromosome 11 in B-ALL patients are  
 case was identified as possessing a triploid/hyperdiploid structural abnormalities in band 11q23, which harbors the  
 karyotype in the iFISH analysis using CEP 11, 17 and 18 myeloid/lymphoid leukemia gene (22).  
 (case A-2, result not shown), as was observed in the cases Chromosomal deletions involving 11q have been reported  
 C-21 and C-22. in certain subtypes of hematological malignancies, including  
 The BIRC3 deletion in B฀ALL case A฀1 was conirmed B-cell CLL, and are associated with a poor prognosis in mantle  
 by aCGH, which reveled that the deletion in the long arm cell lymphomas or T-cell prolymphocytic leukemia (23).  
 of chromosome 11 covered between chr11:67,773,863 and Therefore, the prognosis for the B-ALL patient in the present  
 134,945,165 (GRCh37/hg19) (Fig. 3). The ATM and BIRC3 study may be poor or extremely poor. Additional studies are  
 genes  are  located  between  positions  102,188,181 and required to determine the role of BIRC3 in the prognosis of  
 108,239,826. B-ALL patients.  
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 be interesting for future study. BIRC3, SF3B1, NOTCH1 and MYD88 in a population-based  
 In conclusion, the hypothesis by Rose-Zerilli et al (25) cohort. Leukemia 28: 710-713, 2014.  
 that BIRC3 deletions are always associated with ATM dele- 12. Morgan JA, Yin Y, Borowsky AD, Kuo F, Nourmand N, Koontz JI,  
 tions is questioned at least for a small percentage of cases. As points of the t(11;18)(q21;q21) in mucosa-associated lymphoid  
 screening of the BIRC3 gene is not routinely undertaken for tissue (MALT) lymphoma lie within or near the previously  
 CLL patients (2,26), the results of the present study suggest undescribed gene MALT1 in chromosome 18. Cancer Res 59:  
 that screening may be considered as necessary in the future, 13. Puiggros A, Blanco G and Espinet B: Genetic abnormalities in  
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In chronic lymphocytic leukemia (CLL), presence of acquired cytogenetic abnormalities may help to estimate prognosis. However,
deletion of TP53 gene, which is associated with an aggressive course of the disease and poor prognosis along with a lack of response
to treatment, is one of the alterations which may escape cytogenetic diagnoses in CLL. hus, other techniques have emerged such
as interphase luorescence in situ hybridization (iFISH). Deletion of TP53 may but must not go together with the formation of
an isochromosome i(17q); surprisingly this subgroup of patients was not in the focus of CLL studies yet. his study was about if
presence of i(17q) could be indicative for a new subgroup in CLL with more adverse prognosis. As a result, TP53 deletion was
detected in 18 out of 150 (12%) here studied CLL cases. Six of those cases (∼33%) had the TP53 deletion accompanied by an i(17q).
Interestingly, the cases with i(17q) showed a tendency towards more associated chromosomal aberrations. hese indings may be
the bases for follow-up studies in CLL patients with TP53 deletion with and without i(17q); it may be suggested that the i(17q)
presents an even more adverse prognostic marker than TP53 deletion alone.
1. Introduction
Chronic lymphocytic leukemia (CLL) is a relatively fre-
quently observable acquired disease in men and women of
>50 years of age [1]. Also CLL is a heterogeneousmalignancy,
as the survival of CLL patients can be in the range of months
to decades according to the underlying genetic abnormalities
[2]. he most frequent cytogenetic aberrations in CLL are
involving chromosomal subbands 13q14 (50–60%), 14q32
(12–15%), 11q22 (10–20%), and 17p13 (5–10%) as well as
trisomy 12 (15–25%); each group has diferent prognoses and
survival rates [1, 3]. Deletion of TP53 gene, which is located
in the short arm of chromosome 17 towards the telomeric
region in 17p13.1, is associated with poor prognosis and lack
of response to ludarabine-based regimens.
TP53 deletion in CLL can be associated with isochro-
mosome formation of the long arm of one chromosome
17 leading at the same time to partial monosomy 17p and
partial trisomy 17q. In general, isochromosome i(17q) is the
most frequently observed isochromosome in hematological
malignancies and it can be present as primary or secondary
aberration; that is, it may play roles during development as
well as progression of the malignancy. Presence of i(17q) as a
sole abnormality is associated with a high risk of progression
and an aggressive clinical course, but i(17q) can also be found
as part of a complex karyotype [4–6]. In solid tumors, i(17q) is
reported predominantly in medulloblastoma [7], there oten
associated with c-myc ampliication [8].
Overall, detection of acquired chromosomal abnormali-
ties such as i(17q) just based on GTG-bandingmay be limited
due to low mitotic potential of CLL bone marrow cells. hus,
nowadays other techniques are applied to overcome this prob-
lem, by name interphase luorescence in situ hybridization
(iFISH), multiplex ligation dependent probe ampliication
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(MLPA), and array-comparative genomic hybridization
(aCGH) [2, 9, 10]. Here we studied 150 CLL samples and
concentrated on the questions (i) if i(17q) can be detected
reliably by MLPA and (ii) if i(17q) presence in patients with
TP53 deletion is associated with more complex cytogenetic
aberrations. An association with the clinical outcome would
have been favorable as well; unfortunately this was not
possible due to lack of necessary clinical data.
2. Material and Methods
2.1. Patients and Sample Preparation. he present study
included 150 CLL patients, which were diagnosed according
to standard criteria [11]. he samples were obtained under
informed consent of the corresponding patients and accord-
ing to institutional ethical committee guidelines (Ethical
Committee of the Friedrich Schiller University Jena).
DNA was extracted from lymphocytes of 85 CLL cases
by a commercial kit (Qiagen) according to manufacturer’s
instructions. DNA was derived from diferent sources: 2
samples from heparinized bonemarrow, 8 samples from hep-
arinized blood, and 75 samples from cytogenetically prepared
cells ixed in methanol/acetic acid (3 : 1)—48 of them derived
from bonemarrow and 27 from blood. Details on the studied
patients can be found in the paper by Alhourani et al. (2014):
the 10 here in more detail studied patients with TP53 deletion
(Table 1) were cases 61 (now 1), 1 (now 2), 17 (now 3), 19
(now 4), 12 (now 5), 38 (now 6), 18 (now 7), 16 (now 8), 39
(now 9), and 13 (now 10) from Alhourani et al. (2014) [1].
In the previous study, no special attention was given to the
here treated i(17q) problem, and additional studies, esp. FISH
experiments, and reinterpretation of MLPA and aCGH data
were performed here.
For further investigation of i(17q) status, additional 65
CLL patients were included in this study with special focus
on 8 cases (86 to 93) with TP53 (Table 1).
2.2. GTG-Banding and Interphase-Directed Fluorescence In
Situ Hybridization (iFISH) Analysis. GTG-banding and
iFISH analyses were done as previously reported [1].
For iFISH, the following probes were used:
(i) Abbott/Vysis (Wiesbaden, Germany): LSI p53/LSI
ATM (in 17p13.1 and 11q22.3), LSI D13S319/LSI 13q34/
CEP 12 (in 13q14.3, 13q34, and 12p11.1-q11.1), LSI IGH
dual color, break-apart probe (in 14q32.33), LSI SMS
Region SpectrumOrange/LSI RARA SpectrumGreen
(in 17p11.2 and 17q12-21), CEP 17 (D17Z1 in 17p11.1-
q11.1), TelVysion 17p (282M16/SP6), and TelVysion
17q (D17S928).
(ii) From Zytovision (Bremerhaven, Germany): Zyto-
Light SPEC CMYC/CEN 8 Dual Color (8q24.21 and
8p11.1-q11.1).
(iii) BACPAC Resources Center (Oakland, USA): RP11-
318A15 in 17q25.1 (gene UNC13D) and RP11-94L15 in
17q12 (gene IKZF3).
For each iFISH analysis, 100–200 interphase nuclei were
examined per case and probe.
2.3. Multiplex Ligation Dependent Probe Amplification (MLPA)
Analysis. Multiplex ligation dependent probe ampliication
(MLPA) was performed on 85 CLL cases using SALSAMLPA
probemix P377-A1 for Hematological Malignancies Kit from
(MRC-Holland, Amsterdam, Netherlands).
he P377-A1 probemix kit contains 52 probes for overall
37 genes; TP53 which is located on the short arm of chromo-
some 17 is covered by 4 probes; likewise UNC13D and IKZF3
on q arm were covered by one probe for each of them [1].
2.4. High Resolution Array-Comparative Genomic Hybridiza-
tion (aCGH). High resolution array-comparative genomic
hybridization (aCGH) was performed using Agilent Sure-
Print G3 Human Genome microarray 180K (Agilent Tech-
nologies, Santa Clara, CA, USA) as previously reported [12].
3. Results
Deletion of TP53 has been detected in 9/85 cases by MLPA.
Besides a screening for TP53 deletion was done by iFISH
in all of the studied 85 CLL cases to detect mosaic cases
with low percentage of aberrant cells as well. Accordingly,
TP53 deletion was detected in one additional CLL case, being
present there in only 11.5% of the studied cells (case 10).
he overall detected 10 cases with TP53 deletion (Table 2)
were further studied by iFISH using probes IKZF3 in 17q12,
UNC13D in 17q25.1, and subtelomeric probes (17pter and
17qter; Figure 1(a)); furthermore iFISH-probes for the most
frequent aberrations in CLL and, in part, aCGH (case 3;
Figure 1(b)) have been applied in those cases, as speciied
by Alhourani et al. (2014). So, overall 3/85 (∼3.5%) of here
studied CLL cases had the loss of TP53 due to formation of
an i(17q) which is equal to 30% of these patients.
Further 8 cases with TP53 deletion were found in
additional 65 studied CLL patients by iFISH-probe. Here,
subtelomeric (17pter and 17qter) probes were applied to
identify the three among them cases with i(17q). A probe
for 17p11.2 and 17q12 conirmed the isochromosome status in
those cases (Table 3).
In the here studied cases with i(17q), this alteration
was accompanied by additional chromosomal aberrations
(Table 4). For all of them, ampliication of c-myc was
excluded. While in the irst 85 CLL patients, cases 1 and 2
were accompanied by ive additional acquired chromosomal
rearrangements and case 3 had only one additional change.
In cases 1 and 2, at least one of these additional changes was
correlated with an adverse prognosis; in case 3 the del(13) is
considered to be a favorable prognostic factor. Cases 4–10,
which showed just deletion of TP53 without isochromosome
formation, had either no further aberrations (cases 4 and
9) or just one additional chromosomal alteration associated
with good prognosis (cases 5, 7, and 10). Only case 8 showed
two additional chromosomal alterations with known adverse
prognostic meaning.
Among the 8 cases with TP53 deletion studied only by
iFISH, three cases revealed i(17q). While case 88 showed 8
additional chromosomal rearrangements (two of them were
associated with good prognosis), the other two cases, 86
and 87, had only one additional chromosomal alteration.
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Table 1: Gender, age, and cytogenetic results of the 18 studied CLL cases which showed deletion of TP53 gene.
Case number Gender Age [y]
DNA extracted
from
Banding cytogenetics
1 F 74 bm
46,XX,i(17)(q10)[1]/
46,XX,+12,i(17)(q10),-21[9]/
46,XX,t(3;?)(q2?9;?)[4],-7[4],+12[4],i(17)(q10)[4][cp4]/
46,XX[4]
2 M 83 bm
47,XY,-11,+12,+mar[cp3]/
47,XY,del(5)(p1?3),-11,+12,-17,+mar1,+mar2[cp6]/
46,XY[9]
3 M 72 bm 46,XY
4 F 71 b 46,XX
5 F 50 b n.a.
6 M 65 bm
46,XY,?t(3;?)(p21;?),der(17)t(17;?),-18,+mar[cp7]/
46,XY[9]
7 F 66 b n.a.
8 M 73 bm
46∼47,XY,del(11)(q22q2?3),der(17)t(17;?)(p11.2;?)[cp5]/
45∼46,XY,del(11)(q22q2?3),del(17)(p11.2)[cp4]/
43∼46,XY,del(11)(q22q2?3)[cp2]/
46,XY[7]
9 F 74 B 46,XX
10 F 90 b n.a.
86 M 74 n.a.
45∼46,XY,i(17)(q10)[cp4]/
45,X,-Y[2]/
46,XY[14]
87 F 76 n.a.
46,XX,?t(6;19)(p22;p13),del(17)(p?11.2)[1]
46,XX[16]
88 M 65 n.a.
46,XY,t(10;13)(q2?2;q1?3)[10]
46,XY,i(18)(q10)[1]
45,XY,?del(6)(?q21),-17[1]
46,XY,-17,+mar[1]
44,XY,-11,-17[1]
46,XY,-4,-21,+2mar[1]
46,XY[5]
89 F 68 n.a. n.a.
90 F 63 n.a. n.a.
91 F 79 n.a. n.a.
92 M 61 n.a. n.a.
93 F 75 n.a. n.a.
b = cell pellet in Carnoy’s ixative from blood; bm = cell pellet in Carnoy’s ixative from bone marrow; F = female; M = male; n.a. = not available; B = native
peripheral blood.
he remaining 5 cases with TP53 deletion and no i(17q)
were associated with one additional chromosomal aberration
with good prognosis (cases 89 and 90), or no additional
chromosomal changes (cases 91, 92, and 93) (Table 1).
4. Discussion
Generally, isochromosome formation is characterized by the
loss of the entire short armwith subsequent duplication of the
entire long arm, resulting in two homologous arms attached
to a single centromere as mirror images [4, 7, 13]. here
are two hypotheses to explain the formation of isochromo-
some, either by transverse instead of longitudinal division
of the centromere or by chromatid exchange involving two
homologous chromosomes. he rate of the appearance of
isochromosomes is diferent among the various types of
tumors, with the highest occurrence in germ cell neoplasms
(60%) and the lowest in chronic myeloproliferative disorders
(2.3%) [14].
Surprisingly, although i(17q) appeared in 6/150 (4%) here
studied CLL patients, that is, and 6/18 (∼33%) of CLL patients
with a deletion of TP53, this chromosomal aberration has
not been studied in detail yet in this patient group. Still,
there is one study including 2 CLL patients with i(17q) which
showed that such isochromosome most likely forms due to
clustered breakpoints in 17q11 and is not associated with TP53
mutations of the intact chromosome 17 [4]. In 2006, i(17q)
was found to be present in 4/16 (25%) CLL patients withTP53
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Table 2: Summary of MLPA and iFISH results of IKZF3- and UNC13D-gene speciic probes and subtelomeric probes for chromosome 17 in
10 CLL cases with TP53 deletion in the irst group.
Case number
TP53 [%] UNC13D [%] IKZF3 [%] iFISH [%]
MLPA iFISH MLPA iFISH MLPA iFISH Subtel. pter Subtel. qter
1 d d [95] a a [90] a a [90] d [90] a [90]
2 d d [40] a a [40] a a [40] d [40] a [40]
3 d d [40] n a [25] n a [25] d [25] a [25]
4 d d [36] n n n n n n
5 d d [21] n n n n n n
6 d d [89] n n n n n n
7 d d [19] n n n n n n
8 d d [86] n n n n n n
9 d d [77] n n n n n n
10 n d [11,5] n n n n n n
11 to 85 n n n n.a. n n.a. n.a. n.a.
n = no aberration, d = deletion, a = ampliication, n.a. = not tested, and [] = percentage of cells with aberration.
Table 3: Summary of iFISH results using SMS and RARA gene
speciic probes and subtelomeric probes for chromosome 17 in 8CLL
cases with TP53 deletion in CLL cases only studied by iFISH and not
by MLPA.
Case number
iFISH [%] iFISH [%] iFISH [%]
TP53 Subtel. pter Subtel. qter SMS RARA
86 d [77] d [77] a [77] d [77] a [77]
87 d [77] d [77] a [77] d [77] a [77]
88 d [80] d [80] a [80] d [80] a [80]
89 d [69] n n n.a n.a
90 d [28] n n n.a n.a
91 d [75] n n n.a n.a
92 d [89] n n n.a n.a
93 d [95.5] n n n.a n.a
94 to 150 n n.a n.a n.a n.a
n = no aberration, d = deletion, a = ampliication, n.a. = not tested, and [] =
percentage of cells with aberration.
gene loss [15]; that is, the here reported frequency is within
the same range. However, the initial inding of an i(17q) in
2/21 (9.5%) CLL cases seems to be overestimated due to small
sample size [16].
Even though here only 6 cases with i(17q) could be
studied, the results summarized in Table 4 show a clear ten-
dency: cases with i(17q) are associated with more aberrations
compared to those which have just deletion of TP53. Cases 3
and 8 do not exactly it into this suggestion. However, case 3
had only 25% of the cells with an i(17q) indicating an early
phase of the disease; in case 8 cytogenetics provided a hint on
an ongoing karyotypic evolution and already advanced stage
of the disease.
Whereas both Baliakas et al. and Rigolin et al. reported
that complex karyotype predicts a worse overall survival,
also Baliakas et al. demonstrated that complex karyotype is
identiied as an independent prognostic factor for shorter
time-to-irst-treatment [17, 18].
UNC13D ATM
TP53D17Z1
Subtel. 17pter
Subtel.17qter
(a)
−4 −3 −2 −1 0 1 2 3 4
q25.2
q25.1
q24.3
q23.3
q23.1
q22
q21.32
q21.1
q12
q11.2
p11.2
p12
p13.2
(b)
Figure 1: (a) Isochromosome 17q was detected initially by iFISH
in this case; representative examples for heterozygote deletions of
TP53 and #17 subtelomeric region 17p (subtel. 17pter) besides three
signals forUNC13D and subtel. 17qter. Only 2 signals for centromere
of chromosome 17 (D17Z1) and ATM gene on chromosome 11 were
detected. (b) aCGH showed deletion of short arm and gain of long
arm of chromosome 17 in case 3.
Furthermore, hompson et al. showed that relapsed/
refractory CLL patients who reveal del(17p) and complex
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Del(TP53)
Del(17p) Dup(17q)
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No
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Figure 2: Here a scheme for the suggested procedures how to delineate an i(17q), if cytogenetics, MLPA, and iFISH are available.
Table 4: All 18 CLL cases which revealed TP53 deletion are listed
showing the additionally detected chromosomal aberrations and
their clinical impact (1).
Case number
Additional aberrations
not listing #17 aberrations [%]
Prognosis
1
t(3;?)(q2?9;?)[22] n.a.
-7[22] Adverse
+12[78] Intermediate
del(14)(q32q32)[94] Good
-21[50] n.a.
2
del(5)(p1?3)[33] n.a.
del(11)(q22.3q22.3)[30] Adverse
+12[70] Intermediate
del(13)(q14.3q14.3)[30] Good
rea(14)(q32.33)[28] -> ?+14 Adverse
3 del(13)(q14.3q14.3)[20] Good
4 None detected Intermediate
5
del(13)(q14.2q14.2)[52]
Gooddel(13)(q14.2q14.2)x2[38]
del(13)(q14.3q14.3)[34]
6
t(3;?)(p21;?)[44] n.a.
-18,+mar[44] n.a.
7 del(13)(q14.3q14.3)[90.5] Good
8
amp(8)(q24.21q24.21)[21] Adverse
del(11)(q22.3q22.3)[11] Adverse
9 None detected Intermediate
10 del(13)(q14.3q14.3)x2[98.5] Good
86 -Y n.a.
87 ?t(6;19)(p22;p13),del(17)(p?11.2) Adverse
88
t(10;13)(q2?2;q1?3) Advesrse
i(18)(q10) n.a.
?del(6)(?q21),-17 n.a.
-17,+mar n.a.
-11,-17 n.a.
-4,-21,+2mar n.a.
del(13)(q14.3q14.3)[57] Good
del(14)(q32q32)[75] Good
89
del(13)(q14.2q14.2)[50]
Good
del(13)(q14.2q14.2)x2[7]
90 del(14)(q32q32)[36] Good
91 None detected Intermediate
92 None detected Intermediate
93 None detected Intermediate
n.a. = not available.
karyotype have shorter overall survival than those with only
del(17p) [19].
Due to lack of clinical data, the clinical impact of i(17q)
could not be followed up, but in spite of that the present study
gives irst hints that i(17q) presence may be an indicator for
more aggressive course ofCLLdisease than justTP53deletion
without i(17q) formation. Similar indings were reported
for other hematological neoplasia, like acute lymphocytic
leukemia [20], acute promyelocytic leukemia [21], chronic
myeloid leukemia [5], or other myeloid leukemia [22–24].
As previously outlined by us and others, MLPA is a
quick and inexpensive screening tool for CLL diagnostics
[1, 25]. However, its inability to detect low level mosaics needs
to be considered and thus a diagnostic scheme combining
cytogenetics, iFISH, and MLPA needs to be considered for
reliable testing of CLL cases in diagnostics [1]. hus, in
Figure 2 we suggest a scheme of how to detect i(17q) reliably.
In conclusion, i(17q) presence in CLL cases with TP53
deletion should be considered as a potentially adversemarker
for more aggressive course of the disease than monosomy of
17p13.1 alone; it needs to be kept in mind that MLPA alone
may be not suicient to pick up all corresponding cases and
a combination with iFISH may be considered additionally.
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3. Discussion. 
Diagnosis and prognosis of CLL depend on presence or absence of chromosomal abnormalities, 
which can be detected by different molecular and cytogenetic techniques (Döhner et al. 2000, 
Rodriguez-Vicente et al. 2013). Thus, the first phase of the present work was dedicated to 
identify all possible chromosomal aberrations in 85 CLL cases by using GTG-banding, iFISH, 
MLPA and aCGH in selected cases as discussed in 3.1. As outlined in 3.1.1.-3.1.2., concordance 
and discordance between MPLA and iFISH and the potential clinical relevance for the additional 
detected cases by MLPA are discussed. In 3.1.3. a diagnostic cost efficient scheme combining 
the different techniques is suggested. 
Furthermore, in this thesis the disruption of BIRC3 gene was studied in 117 CLL-, and 45 B-
ALL cases and the association between BIRC3 disruption and deletion of ATM gene was 
analyzed (3.2.). Finally i(17q) status was examined in 150 CLL, and potential i(17q)-association 
with complex karyotypes. 
 
3.1. Cytogenetic analysis for CLL diagnostics 
Prognosis and hence treatment decisions for CLL patients vary according to the detected 
chromosomal abnormalities. The identification of such aberrations by conventional karyotyping 
and metaphase-directed FISH is obstructed by a low in vitro mitotic activity of malignant cells, 
which leads to the lack of the metaphase spreads in the analyzable sample (article 1, Döhner et 
al. 2000). Accordingly, iFISH has been introduced as a powerful tool for the detection of 
genomic aberrations in CLL, as it can be performed in both dividing and non-dividing cells, by 
that overcoming the limitation of low mitotic index. Still it is restricted to specific chromosomal 
regions according to the used probes panel (e.g. 13q14.3, 12p11.1-q11.1, 14q32.33, 17p13.1 and 
11q22.3 in CLL (Rodriguez-Vicente et al. 2013, Haferlach et al. 2007). MLPA technique may be 
applied in CLL diagnostics to detect copy number variations in multiple chromosomal regions at 
the same time. Thus one of the objectives of this study was the evaluation of MLPA efficacy in 
identification of unbalanced genomic aberrations in CLL in comparison with GTG-banding and 
iFISH (article 2, Véronèse et al. 2013). 
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3.1.1. Concordances of MLPA and iFISH results  
MLPA has been performed retrospectively on 85 CLL samples, which were initially studied by 
GTG-banding and routine iFISH. Overall MLPA and iFISH were in concordance in 70% of 
cases. However, 33 additional chromosomal aberrations were detected by MLPA, 30 of them 
confirmed later by iFISH (article 2). 
The additional detected aberrations had an impact on the prognosis of individual CLL cases. 12 
cases with known deletion in 13q14.3 revealed additional loss of 13q14.2; this implied a 
regrouping from favorable into unfavorable group (article 2, Dal Bo et al. 2011, Rodriguez-
Vicente et al. 2013). 
Also according to MLPA results previously unrecognizable deletions in the long arm of 
chromosome 6 were identified in 2 cases, being considered as an intermediate-risk factor, 
leading to short TTFT and OS (article 2, Cuneo et al. 2004). 
In addition to that 3 cases had 2p amplification; they were associated with deletion in ATM in 
two cases and deletion in 6q in the third one. Fabris et al. (2013) reported that 2p gain which 
include MYCN gene can be present since the early stages of the disease, particularly in those 
cases characterized by other poor prognosis markers, i.e. del(11)(q23) and del(17)(p13). A more 
aggressive course of the disease was associated to those patients. Thus 2p amplification can be 
an indicator for poor prognosis with short OS (article 2, Fabris et al. 2013). 
Only one case of this study showed trisomy 18 accompanied with trisomy 12; this changed the 
prognosis of this patients to be more adverse compared to such with only trisomy 12. Another 
case revealed duplication in 8q24 (MYC) accompanied with deletion in TP53 and ATM genes. 
This aberration (Dup MYC) is considered as a rare one in CLL, and to be associated with shorter 
OS (article 2, López et al. 2012, Puiggros et al. 2014). 
Duplication of RUNX1 gene (21q22.12), also called AML1-gene, showed up in two cases of this 
study; in one of them as a sole abnormality, and in the second one it was accompanied by 
deletions in 6q ,13q14.3, and gains in 2p. Normally, amplification in RUNX1 (AML1) gene 
appears in acute lymphoblastic leukemia and not in CLL, and is associated with a poor outcome. 
In addition to that translocation of this gene has been reported to be involved in a novel three-
way variant t(8;13;21)(q22;q33;q22) in a child with acute myeloid leukemia (articles 2, 3, 
Robinson et al. 2003). 
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3.1.2. Discordances of MLPA and iFISH results 
The results of array-CGH and iFISH showed no alterations in the chromosomal regions for the 
three aberrations (Dup in RNMT, DCC, SMOC2) being identified by MLPA, as well; thus, they 
have been considered as false positive results. This leads to the conclusion that genetic 
aberrations, which are detected by MLPA technique, especially those chromosomal regions 
which are covered by a single probe in the MLPA kit, should be confirmed or falsified by 
another molecular genetic technique such as iFISH (article 2, Hömig-Hölzel et al. 2012). 
Although the used MLPA kit (SALSA MLPA probemix P377-A1 for Hematological 
Malignancies) has the ability to detect 37 target regions simultaneously, the overall by MLPA 
detected alteration was only 58% of the 163 aberrations, while routine iFISH test, which applied 
only 5 probes, revealed 61% of the overall present aberrations (article 2). 
These unexpected results could be explained partly by the absence of probes targeted against 
chromosomal region 14q32 (IGH locus) in the MLPA kit, as this region is considered among the 
most frequent chromosomal regions being altered in CLL. IGH aberration were detected in this 
study by routine iFISH in 16 cases (article 2, Quintero-Rivera et al. 2009). 
Also the cases with low percentage of aberrant cells (10% up to 34% of the cells being aberrant) 
could be missed by MLPA. Surprisingly in this study there cases were also detectable by MLPA 
with percentage of aberrant cells down to ~10% according to iFISH, and other cases with 34% of 
aberrant cells after iFISH could not be picked up by MLPA (article 2, Hömig-Hölzel et al. 2012). 
Few previous studies reported the MLPA detection rates of low level mosaic CLL cases. 
Whereas, Coll-Mulet et al. (2008) and Abdool et al. (2010) demonstrated that false-negative 
MLPA results appeared in samples with less than 25% and 20% of aberrant cells, respectively, 
Véronèse et al. (2013) suggested that all false-negative cases occur in cases with 12-21% of 
aberrant cells. Thus it was estimated that 25-30% aberrant cells are sufficient for reliable 
detection by MLPA, which is definitely less sensitive than iFISH detection (Véronèse et al. 
2013). On the other hand Al Zaabi et al. (2010) demonstrated that MLPA can reliably detect the 
13q14 deletion in samples containing at least 36% of aberrant cells. 
Still, the findings of this study are in concordance with Stevens-Kroef et al. (2009) who reported 
that the detection limit of MLPA could be down to 10% of abnormal cells, and they found an 
almost perfect correlation between MLPA and iFISH, as long as identical genetic regions were 
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tested. Finally, false negative MLPA results can be also due to the technical impossibility of 
MLPA in detection of balanced translocations (Hömig-Hölzel et al. 2012). 
 
3.1.3. The combination of the different techniques in a CLL leads to a cost efficient 
diagnostic scheme.  
In spite of the application of iFISH and other molecular techniques for the detection of 
chromosomal abnormalities in CLL, GTG-banding is still considered as the golden standard 
method, as it enables the untargeted search for gross chromosomal aberrations. In the present 
study this general statement (Keen-Kim et al. 2008, Wan et al. 2012) was confirmed, as 15 
(~9%) of the 163 detected aberrations were identified exclusively by banding-cytogenetics 
(articles 1, 2). 
For a better assessment of the prognosis and the diagnosis of CLL, a cost efficient diagnostic 
scheme is needed and has been suggested, which combines three techniques together in a 
systematic way based on the detected chromosomal aberrations (article 2). According to the 
revealed chromosomal abnormalities by GTG-banding, the next test which has been suggested to 
be done is MLPA. As shown MLPA and routine iFISH have in principle comparable detection 
rates in CLL, but MLPA covers a more broad spectrum of target genes and also it is more cost 
efficient than iFISH (article 2, Hömig-Hölzel et al. 2012). 
The detection of an adverse diagnostic aberration by any of the applied methods in the 
recommended order is considered the end point of the tests to be done for an individual case. 
Thus for example it would be adequate if such an adverse acquired chromosomal aberration 
would be detected already by GTG-banding, no further procedures should be applied. 
If the suggested diagnostic scheme would have been applied in the studied 85 CLL patients, 
iFISH would have been not necessary to be performed in 20 of them, as MLPA would have 
already identified one or more adverse chromosomal abnormalities. 
Also four patients would have been classified in intermediate prognosis group after the 
application of MLPA, and then only three probes for the adverse prognosis aberrations would 
have been enough for iFISH test. 
For the 29 cases which were normal according to MLPA results, all routine iFISH probes should 
be applied for the detection of the low level mosaics cases. So based on iFISH results 4, 1, and 6 
cases went to adverse, intermediate, and good prognosis, respectively. 
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The CLL patients with good prognosis aberrations could be classified into favorable or 
unfavorable subgroups according to the size and /or percentage of the aberrant cells, also 
biallelic deletions in 13q14 which could be recognized by iFISH has been considered to be in the 
unfavorable subgroup. Thus, for 32 patients who revealed good prognosis aberrations according 
to MLPA, the same iFISH probes as for normal MLPA results should be applied (Garg et al. 
2012, Puiggros et al. 2014). 
If only MLPA and iFISH methods would have been applied for the studied 85 patient, in this 
situation still 3 cases would have been misclassified, as GTG-banding revealed poor prognostic 
aberrations in two of the cases, and intermediate-type aberration in the third one. Thus GTG-
banding has been suggested to be the initial test for CLL diagnostics. Irrespective of that also 
two cases were normal by GTG-banding and iFISH but after the application of MLPA one of 
them showed del 6q and the other one revealed Dup RUNX, which showed the importance of 
additional MLPA test performance for a better prognosis of CLL disease.  
The application of the suggested scheme would minimize the number of the applied iFISH 
probes, as 344 instead of 425 iFISH-probes, i.e. 20% less would be used (article 2). 
 
3.2. BIRC3 disruption in CLL and B-ALL 
Attempts for a precise prognosis are undertaken to lead later to effective treatment regimens for 
CLL patients. Unfortunately the molecular basis for a subgroup of patients who experience an 
aggressive clinical course of the disease is still unclear, as they tend to have refractory and/or 
relapsed towards fludarabine-based regimens, which are generally considered as the first line 
treatment for CLL. However, ~40% of those CLL-patients are associated with TP53 
abnormalities and thus the activation of the nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) pathway could play a role in the mechanism of this therapy resistance. 
BIRC3 gene is considered as a negative regulator of the non-canonical pathway of NF-κB. 
Disruption of BIRC3 in CLL leads to the proliferation of cells and resistance to apoptosis due to 
activation of NF-κB which regulates anti-apoptotic genes especially the TRAF1 and TRAF2 
(Rossi et al. 2013, Sun SC et al.  2011). 
The previously reported aberrations which are related to BIRC3 were either disruption in CLL or 
recurrent translocation t(11;18)(q21;q21) in mucosa associated lymphoid tissue (MALT) 
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lymphoma (Dierlamm et al., 1999, Rose-Zerilli et al., 2014, Morgan et al., 1999, Rosebeck et al., 
2011). 
Based on the results of a previous study, which included 637 CLL patients, the disruption of 
TP53 and/or BIRC3 has been considered as high risk prognostic factors. As BIRC3 disruption did 
not appear in the fludarabine sensitive patients, an association with chemo-refractory CLL 
subtype was suggested (Rossi et al. 2013.) 
As the BIRC3 gene is located in 11q22.2 next to the ATM gene locus, the objective of this study 
was the evaluation if there is an association between BIRC3 and ATM abnormalities in CLL (117 
cases) – especially to answer the question if BIRC3 and ATM deletion appear simultaneously. 
Furthermore, 45 B-ALL patients having the same original subtype of affected cells (B 
lymphocytes) were studied for presence of BIRC3 alterations were (article 4, Puiggros et al. 
2014). 
BIRC3 duplication was detected in 3 CLL cases; two of them were due to a hyperdiploid status, 
which has been reported in CLL earlier, but not as a frequent event. Interestingly, the third CLL 
case had the BIRC3 duplication as a sole abnormality, and the clinical impact of this is not 
known yet. Still, the duplication of BIRC3 in that case was not detected by array-CGH, most 
likely due to the limitation of array-CGH in detection cases with low percentage of aberrant 
cells, despite being present in 36% of the cells, here (article 4, Shao et al. 2010, Specchia et al. 
2002). 
The unexpected result of BIRC3 amplification could be explained by the tumor suppressive role 
of NF-κB via its non-canonical pathway which has been reported by Keller et al. (2010). Also 
several studies found that NF-κB mediates apoptosis in a variety of cell types, as the activation 
of NF-κB promotes the ability of TP53 to induce apoptosis, and by this NF-kB plays an essential 
in p53-mediated apoptosis. It is notable that the studied case with sole BIRC3 duplication is 
associated with normal TP53 status. Taking together what is known about the interaction 
between BIRC3 and NF-κB pathway, it has been proposed that BIRC3 duplication could lead to 
inactivation of tumor suppressor activity ( article 4, Ryan et al., 2000,  Liu et al., 2012, Jing et al. 
2014).  
Also one of the B-ALL cases showed BIRC3 duplication as a part of hyperdiploidy. A 
hyperdiploid status appears more frequently in B-ALL compared to CLL, and it has a good 
prognosis in pediatric patients (Kebriaei et al. 2002). 
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Previously it was reported that BIRC3 mutations are selectively restricted to CLL, while they are 
absent in other lymphoid tumors which are representative of the main categories of mature B-cell 
neoplasms (diffuse large B-cell lymphoma, Burkitt lymphoma, follicular lymphoma, extranodal 
marginal zone lymphoma, hairy-cell leukemia, and multiple myeloma). Therefore the second 
important finding of this study is the detection of a BIRC3 deletion in one of the 45 studied B-
ALL cases. Based on array-CGH result, the deletion included almost the whole long arm of 
chromosome 11. The most frequent aberration in B-ALL related to chromosome 11 is the 
structural abnormality of the 11q23 band harboring the MLL (myeloid/lymphoid leukemia) gene 
translocation in 3% to 7%, and being associated with an extremely poor prognosis (article 4, 
Rossi et al. 2012, Cox et al. 2004). 
Chromosomal deletions involving 11q have been reported also in other subtypes of 
hematological malignancies, such as B-cell chronic lymphocytic leukemia (B-CLL), which is 
associated with a poor prognosis, and also in mantle cell lymphomas (MCL) and T-cell 
prolymphocytic leukemia (T-PLL) (Monni et al. 2001). 
Based on that, the prognosis for the B-ALL case with BIRC3 deletion could be poor or extremely 
poor. But it remains to be determined if in such cases BIRC3 may also play a role for prognosis 
in B-ALL, as it does in CLL (Cox et al., 2004). 
Although the frequency of BIRC3 disruption is low at diagnosis, it tends to accumulate among 
refractory CLL patients, as it has been reported selectively in fludarabine-refractory patients with 
normal TP53. In this study BIRC3 abnormalities were associated with TP53 deletion in only 
4/117 CLL cases (article 4, Rossi et al. 2012). 
Overall, based on the results of this study, ATM deletions may, but not always must be, associate 
with BIRC3 abnormalities, as one of the CLL cases also showed BIRC3 duplication with normal 
ATM gene status acc. to MLPA. Therefore, the screening of BIRC3 in CLL patients is 
recommended particularly for correct treatment decisions and especially to decide whether to 
treat with or without fludarabine regime (article 4). 
 
3.3. Isochromosome 17q in CLL. 
As previously mentioned, among CLL patients with TP53 deletion there is a subgroup suffering 
from relapsed and/or refractory disease towards the used treatment regimens. It was previously 
suggested that deletion of TP53 in CLL patients could be associated with the formation of 
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isochromosome 17q [i(17q)], which is described as a duplication of the whole long arm with a 
simultaneous deletion of the whole short arm. In addition to that, the appearance of a complex 
karyotype in CLL has been considered as a poor prognostic feature. Here overall 150 CLL 
patients were studied for possible correlation of i(17q) presence and complex karyotype (article 
5, Puiggros et al. 2014, Scheurlen et al. 2004). 
 
3.3.1. The detection rate of i(17q) by MLPA 
In addition to that the assessment of MLPA in the detection of i(17q) in the first studied 85 CLL 
cases (article 2) 65 more cases were studied by iFISH experiments, and array-CGH in selected 
cases (article 5). 
The used MLPA kit (SALSA MLPA probemix P377-A1) includes 4 probes for TP53 gene, 
which is located on the short arm of chromosome 17, and one probe each for UNC13D and 
IKZF3 genes, which are located on the long arm of chromosome 17. The presence of an i(17q) 
appears as deletion of TP53 with concomitant duplication of UNC13D and IKZF3 genes (article 
5). 
Based on the results, a diagnostic scheme combining GTG-banding, MLPA, and iFISH has been 
suggested for special detection of i(17q) cases (article 5). GTG- banding is proposed to be the 
first test to be done, later MLPA should be performed, and if an i(17q) has not identified by 
banding cytogenetics and MLPA further iFISH tests should be performed by using subtelomeric 
probes for chromosome 17, to detect the cases with low percentage of the aberrant cells (article 
5). 
Among 85 cases which have been studied by GTG-banding, MLPA, and iFISH. The presence of 
i(17q) has been identified in 2 out of 3 cases by MLPA, and the third case was detected by 
iFISH, only, and later confirmed by array-CGH. Also an i(17q) was identified already by GTG-
banding in one case among them. 
 
3.3.2. Association between i(17q) and complex karyotype 
Overall among 150 CLL patients, deletion of TP53 was detected in 18 (12%) cases; among those 
i(17q) has been identified in 6 (∼33%) cases (article 5). Previously one study demonstrated that 
the formation of i(17q) is most likely due to clustered breakpoints in 17q11 and is not associated 
with TP53 mutations of the intact chromosome 17 (Fioretos et al. 1999). 
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Whereas the detection rate of i(17q) in the present study is almost in concordance with the 
previously reported in 2006, which was 25%; the initial finding of an i(17q) in 2/21 (9.5%) CLL 
cases by Vahdati et al. (1989) seems to be overestimated due to small sample size (Fink et al. 
2006). 
According to the results presented here, it was obviously that complex karyotypes are more 
frequently in cases with i(17q) compared to the cases with just deletion of TP53. In addition to 
that, all here studied the cases with i(17q) showed associated aberrations, four of them were 
considered as poor prognosis, while among 12 cases with only TP53 deletion, just one case 
showed concomitant poor prognosis aberrations, and 5 cases did not show any other 
chromosomal aberrations (article 5). 
Several studies reported complex karyotypes as an indicator for a short OS and shorter TTFT 
(Rigolin et al. 2015, Baliakas et al. 2014). 
Moreover, it was also demonstrated that the association between del(17p) and complex 
karyotype in the relapsed/ refractory CLL patients decreases the overall survival in comparison 
to those patients with only del(17p) (Thompson et al. 2015). 
Due to lack of clinical data in the present study, the impact of i(17q) on the clinical course of the 
disease could not be followed up. Still this study suggested the association of i(17q) and complex 
karyotype, that presence of i(17q) could be an indicator for more aggressive course of CLL 
disease than just TP53 deletion without the presence of i(17q). 
Furthermore, the presence of i(17q) was reported as an adverse cytogenetic feature in other 
hematological neoplasia, like acute lymphocytic leukemia, acute promyelocytic leukemia, 
chronic myeloid leukemia, or other myeloid leukemia (Pui et al. 1988, Duan et al. 2013, 
McClure et al. 1998, Becher et al. 1990, Sousa et al. 2012). 
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4. Conclusions and outlook 
The identification of, after GTG-banding cryptic chromosomal / genetic aberrations in CLL is 
necessary for a precise prognosis and thus correct determination of treatment protocols. 
Although cytogenetics and molecular cytogenetics are and will continue to be indispensable tools 
in leukemia diagnostics, each technique has its own limitations and advantages. The present 
work highlights that only the combination between cytogenetics, molecular genetics and 
molecular cytogenetics can lead to most comprehensive insights into the (cyto)genetic 
abnormalities in CLL. Thus, all the three techniques should be used for accurate diagnosis and 
therapeutic decisions for CLL patients according to the cost efficient suggested scheme: 
MLPA should be applied as an initial test if routine cytogenetics is not possible or non-
informative as it has the ability to detect rare chromosomal aberrations in CLL, according to the 
obtained MLPA-results iFISH should be performed when it is needed to distinguish mono- from 
biallelic deletions and also to avoid missing of aberrations being present only at low percentages 
of the studied cells. 
Furthermore, according to the results of the present study BIRC3 abnormalities are not always 
going together with ATM deletions. Thus screening of BIRC3 may be considered as necessary in 
future, particularly to help taking the accurate treatment decisions. 
As deletion of TP53 can be associated with the formation of an i(17q) and the latter is associated 
with more aggressive disease course this aberration should be specifically checked in TP53-
deletion cases. However, MLPA alone is not sufficient to pick up all corresponding cases and a 
combination with iFISH should be considered additionally.  
Overall the questions studied in this thesis could be answered as follows: 
1. How many cryptic chromosomal aberrations in the 85 studied CLL cases could be detected 
by MLPA, in comparison with routine iFISH and GTG-banding? 
Overall 163 aberrations were identified. 15 of those (~9%) were exclusively detected by banding 
cytogenetics, 95 were found by MLPA (~58%) and 100 (~61%) by routine iFISH. 
2. Could the underlying chromosomal abnormalities in CLL be precisely identified, to avoid 
misinterpretation of the prognosis so subsequently incorrect treatment regimens? 
Based on the obtained results a cost efficient diagnostic scheme is proposed combining GTG-
banding, MLPA, and iFISH for a better diagnosis and thus treatment for CLL patients. 
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3. What is the percentage of BIRC3 disruption in the studied 117 CLL cases, and its 
correlation with ATM deletion? 
Genetic abnormalities of BIRC3 were detected in 23/117 (~20%) of CLL, and one of the CLL 
cases showed duplication of BIRC3 without any alteration in ATM. 
4. Is BIRC3 disruption specific only for CLL? 
No, as BIRC3 abnormalities were detected in 2/45 (~4%) studied B-ALL cases.  
5. Is presence or absence of i(17q) in CLL able to identify a new subgroup with more 
aggressive clinical course of the disease, and what is the best way for its detection? 
A scheme has been proposed for the detection of i(17q) combining GTG-banding, MLPA, and 
iFISH, and it was demonstrated that i(17q) is more frequently associated with complex 
karyotypes. Thus i(17q) presence is considered as a hint for identification of a subgroup with 
more aggressive clinical course of the disease. 
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6. Appendix 
6.1. List of tables 
Supplementary Table 1 (Article 2) 
Gender, age and cytogenetic results of the studied cases/ samples.  
Abbreviations: b = cell pellet in Carnoys fixative from blood; B = native blood; bm = cell pellet 
in Carnoys fixative from bone marrow; BM = native bone marrow; F = female; M = male;  
case / 
sample 
number 
gender Age [y] DNA 
extracted 
from 
Cytogenetics 
1 M 83 bm 47,XY,-11,+12,+mar[cp3]/ 
47,XY,del(5)(p1?3),-11,+12,-17,+mar1,+mar2[cp6]/ 
46,XY[9] 
2 M 68 bm 46,XY 
3 F 62 B n.a. 
4 M 72 b 47,XY,?t(2;14),+12[3]/ 
45,X,-Y[4]/46,XY[11] 
5 M 65 b 46,XY 
6 M 71 bm 46,XY 
7 M 50 bm 46,XY 
8 F 64 bm 46,XX 
9 F 55 bm 46,XX 
10 F 39 bm 43~46,XY,del(11)(q2?2q2?4)[cp5]/  
45~46,XY,del(11)(q2?2q2?4),del(15)(q1?1q2?3)[cp11]/ 
46,XY[1] 
11 F 66 B 46,XX 
12 F 50 b n.a. 
13 F 90 b n.a. 
14 M 64 bm 46,XY 
15 M 43 bm 46,XY 
16 M 73 bm 46~47,XY,del(11)(q22q2?3),add(17)t(17;?)(p11.2;?)[cp5]/ 
45~46,XY,del(11)(q22q2?3),del(17)(p11.2)[cp4]/ 
43~46,XY,del(11)(q22q2?3)[cp2]/ 
46,XY[7] 
17 M 72 bm 46,XY 
18 F 66 b n.a. 
19 F 71 b 46,XX 
20 F 74 b 46,XX 
21 M 71 bm 46,XY 
22 F 76 b 46,XX 
23 M 62 b 46,XY 
24 M 67 bm 46,XY 
25 M 83 b n.a. 
26 M 79 B n.a. 
27 F 73 bm 46,XX 
28 F 49 B 46,XX 
29 F 69 b n.a. 
30 M 78 b 46,XY 
31 M 74 bm 46,XY 
32 M 71 b 45,X,-Y[cp8]/ 
46,XY[10] 
33 F 63 bm 46,XX 
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Supplementary Table 1 (Article 2 - continued) 
case / 
sample 
number 
gender age [y] 
 
DNA 
extracted 
from 
Cytogenetics 
34 M 77 bm 46,XY,del(11)(q?21),add(20)(p13)[7]/ 
45,X,-Y[10]/ 
46,XY[3] 
35 M 53 bm 46,XY 
36 M 73 bm 45,X,-Y,t(9;22)(q34;q11) 
37 M 74 bm 45,X,-Y[2]/ 
47,XY,+12[1]/ 
48,XY,-6,-8,+12,+mar,+mar,+mar[1]/ 
46,XY[14] 
38 M 65 bm 46,XY,?t(3;?)(p21;?),add(17)(p?12) or t(17;?),-18,+mar[cp7]/ 
46,XY[9] 
39 F 74 B 46,XX 
40 F 72 b 46,XX 
41 M 72 bm 45,X,-Y[4]/ 
46,XY[16] 
42 M 51 bm 46,XY 
43 F 48 b 46,XX 
44 F 47 b 46,XX 
45 F 79 bm 46,XX 
46 M 67 bm n.a. 
47 M 67 bm n.a. 
48 M 68 bm 46,XY 
49 M 61 b 46,XY 
50 M 73 bm 46,XY 
51 M 75 bm 46,XY 
52 M 77 b n.a. 
53 M 54 b 46,XY 
54 M 59 bm n.a. 
55 M 59 b 46,XY 
56 F 47 B 46,XX 
57 M 71 bm 46,XY,der(1)(t(1;4)(q1?2;q?31),der(4)t(4;?10)(q?31;q24), 
?der(10)t(10;16)(q24;p?11.2),der(15)t(1;15)(q1?2;q1?2), 
der(16)t(15;16)(q1?2;p?11.2)[17]/ 
46,XY[2] 
58 M 73 bm 45,XY,der(2)t(2;13)(q?37;q?14),?del(6)(p?23),del(11)(q?21), 
der(12)t(12;13)(q?24;q?22),-13[cp4]/46,XY[19] 
59 M 72 bm 46,XY 
60 M 54 B n.a. 
61 F 74 bm 46,XX,i(17)(q10)[1]/ 
46,XX,+12,i(17)(q10),-21[9]/ 
46,XX,t(3;?)(q2?9;?)[4],-7[4],+12[4],i(17)(q10)[4][cp4]/ 
46,XX[4] 
62 F 65 bm 46,XX 
63 M 72 b n.a. 
64 F 73 bm 46,XX,add(11)(q?22)[3]/ 
46,XX[12] 
65 M 54 b 46,XY 
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66 F 69 bm 46,XX 
67 M 53 bm 46,XY 
Supplementary Table 1 (Article 2 - continued) 
case / 
sample 
number 
gender age [y] DNA 
extracted 
from 
Cytogenetics 
68 M 53 b 46,XY 
69 M 75 bm 46,XY 
70 M 56 b 46,XY,?add(1q)(q4)[3]/ 
46,XY[3] 
71 F 58 BM n.a. 
72 F 73 B n.a. 
73 M 66 bm 46,XY 
74 M 74 bm 46,XY 
75 F 51 bm 46,XX 
76 M 52 bm 46,XY 
77 M 63 bm n.a. 
78 M 60 b 46,XY 
79 M 72 b n.a. 
80 F 49 bm 46,XX 
81 F 64 bm 46,XX 
82 F 72 bm 46,XX 
83 M 82 b 46,XY 
84 M 74 BM 46,XY 
85 F 72 bm n.a. 
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Supplementary Table 2 (Article 2)  
Aberrations detected in 85 CLL samples and by which method the corresponding aberrations could be 
detected. Abbreviations: + = detected, (+) = detected but not specific as bi- or monoallelic deletion, o = 
not tested, - not detected, n = no aberration. 
sample 
number 
aberrations [%] iFISH 
routine 
MLPA iFISH 
confirmatory for 
MLPA 
1 del(5)(p1?3)[33] 
del(11)(q22.3q22.3)[30] 
+12[70] 
del(13)(q14.3q14.3)[30] 
rea(14)(q32.33)[28] -> ?+14 
del(17)(p13.1p13.1)[16] 
amp(17)(q25.1q25.2)[40] 
o 
+ 
+ 
+ 
+ 
+ 
o 
o 
- 
+ 
+ 
o 
+ 
+ 
o 
o 
o 
o 
o 
o 
+ 
2 del(11)(q22.3q22.3)[33] 
del(13)(q14.3q14.3)[18] 
del(13)(q14.3q14.3)x2[14] 
+ 
+ 
+ 
- 
+ 
(+) 
o 
o 
o 
3 +12[15] 
rea(14)(q32.33)[52] -> 
t(14;18)(q32;q21) 
+ 
+ 
- 
o 
o 
o 
4 +12[31] 
del(13)(q14.2q14.2)[45] 
del(13)(q14.3q14.3)[20] 
+ 
o 
+ 
- 
+ 
+ 
o 
+ 
o 
5 amp(2)(p24.3p24.3)[60] 
amp(2)(p23.2~23.1p23.2~23.1)[63] 
del(6)(q23.3q23.3)[68] 
del(6)(q25.1q25.1)[65] 
del(6)(q27q27)[23] 
del(13)(q14.3q14.3)[18] 
del(14)(q32q32)[65]  
amp(21)(q22.12q22.12)[86] 
o 
o 
o 
o 
o 
+ 
+ 
o 
+ 
+ 
+ 
+ 
+ 
- 
o 
+ 
+ 
+ 
+ 
+ 
+ 
o 
o 
+ 
6 del(13)(q14.3q14.3)[10] + - o 
7 del(13)(q14.3q14.3)[10.5] + - o 
8 del(13)(q14.3q14.3)[12] + - o 
9 del(13)(q14.3q14.3)[18.5] + - o 
10 del(11)(q22.3q22.3)[98] 
del(13)(q14.3q14.3)[25] 
+ 
+ 
+ 
- 
o 
o 
11 del(13)(q14.3q14.3)[34] + - o 
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Supplementary Table 2 (Article 2 - continued)  
sample 
number 
aberrations [%] iFISH 
routine 
MLPA iFISH 
confirmatory for 
MLPA 
12 del(13)(q14.2q14.2)[52] 
del(13)(q14.2q14.2)x2[38] 
del(13)(q14.3q14.3)[34] 
del(17)(p13.1p13.1)[21] 
o 
o 
+ 
+ 
+ 
(+) 
- 
+ 
+ 
+ 
o 
o 
13 del(13)(q14.3q14.3)x2[98.5] 
del(17)(p13.1p13.1)[11.5] 
+ 
+ 
+ 
- 
o 
o 
14 del(11)(q22.3q22.3)[23.5] 
del(13)(q14.3q14.3)[34] 
+ 
+ 
+ 
+ 
o 
o 
15 del(11)(q22.3q22.3)[24] + + o 
16 amp(8)(q24.21q24.21)[21] 
del(11)(q22.3q22.3)[11] 
del(17)(p13.1p13.1)[86] 
o 
+ 
+ 
+ 
+ 
+ 
+ 
o 
o 
17 del(13)(q14.3q14.3)[20] 
del(17)(p13.1p13.1)[40] 
+ 
+ 
+ 
+ 
o 
o 
18 del(13)(q14.3q14.3)[90.5] 
del(17)(p13.1p13.1)[19] 
+ 
+ 
+ 
+ 
o 
o 
19 del(17)(p13.1p13.1)[36] + + o 
20 del(13)(q14.3q14.3)x2[94] 
del(14)(q32q32)[97] 
+ 
+ 
+ 
o 
o 
o 
21 del(13)(q14.2q14.2)[50] 
del(13)(q14.2q14.2)x2[30] 
del(13)(q14.3q14.3)x2[91] 
o 
o 
+ 
+ 
(+) 
+ 
+ 
+ 
o 
22 del(13)(q14.3q14.3)[5] 
del(13)(q14.3q14.3)x2[75] 
+ 
+ 
(+) 
+ 
o 
o 
23 del(13)(q14.3q14.3)[5] 
del(13)(q14.3q14.3)x2[81] 
+ 
+ 
(+) 
+ 
o 
o 
24 del(11)(q22.3q22.3)[88] 
del(13)(q14.2q14.2)[36] 
del(13)(q14.2q14.2)x2[41] 
del(13)(q14.3q14.3)[16] 
del(13)(q14.3q14.3)x2[71] 
+ 
o 
o 
+ 
+ 
+ 
+ 
(+) 
(+) 
+ 
o 
+ 
+ 
o 
o 
25 del(13)(q14.2q14.2)[66]  
del(13)(q14.2q14.2)x2[21] 
del(13)(q14.3q14.3)[18] 
del(13)(q14.3q14.3)x2[77] 
o 
o 
+ 
+ 
+ 
(+) 
(+) 
+ 
+ 
+ 
o 
o 
26 del(13)(q14.3q14.3)[25] 
del(13)(q14.3q14.3)x2[65] 
+ 
+ 
+ 
(+) 
o 
o 
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Supplementary Table 2 (Article 2 - continued)  
sample 
number 
aberrations [%] iFISH 
routine 
MLPA iFISH 
confirmatory for 
MLPA 
27 del(13)(q14.2q14.2)[34] 
del(13)(q14.2q14.2)x2[27] 
del(13)(q14.3q14.3)[36.5] 
del(13)(q14.3q14.3)x2[24] 
del(14)(q32q32)[12]  
o 
o 
+ 
+ 
+ 
+ 
(+) 
+ 
(+) 
o 
+ 
+ 
o 
o 
o 
28 del(13)(q14.3q14.3)[81] 
del(13)(q14.3q14.3)x2[7] 
+ 
+ 
+ 
(+) 
o 
o 
29 del(13)(q14.2q14.2)[58] 
del(13)(q14.2q14.2)x2[24] 
del(13)(q14.3q14.3)[86] 
del(13)(q14.3q14.3)x2[9] 
o 
o 
+ 
+ 
+ 
(+) 
+ 
(+) 
+ 
+ 
o 
o 
30 del(13)(q14.3q14.3)x2[100] + + o 
31 del(14)(q32q32)[92] + o o 
32 del(14)(q32q32)[81] 
-Y[44] 
+ 
o 
o 
o 
o 
o 
33 del(14)(q32q32)[58] + o o 
34 del(11)(q22.3q22.3)[90] 
del(14)(q32q32)[90] 
-Y[50] 
+ 
+ 
o 
+ 
o 
o 
o 
o 
o 
35 del(11)(q22.3q22.3)[77] + + o 
36 t(9;22)(q34;q11)[94] + o o 
37 +12[49.5] + + o 
38 t(3;?)(p21;?)[43] 
del(17)(p13.1p13.1)[89] 
o 
+ 
o 
+ 
o 
o 
39 del(17)(p13.1p13.1)[77] + + o 
40 del(13)(q14.3q14.3)[52] + + o 
41 del(13)(q14.3q14.3)[60] 
-Y[80] 
+ 
o 
+ 
o 
o 
o 
42 del(13)(q14.3q14.3)[68] + + o 
43 
 
del(13)(q14.3q14.3)[70.5] + + o 
44 del(13)(q14.3q14.3)[73] + + o 
45 del(13)(q14.3q14.3)[73] + + o 
46 del(13)(q14.3q14.3)[80] + + o 
47 del(13)(q14.3q14.3)[80] + + o 
48 del(13)(q14.3q14.3)[81] + + o 
6. Appendix                                                                                                                                                               88   
Supplementary Table 2 (Article 2 - continued)  
sample 
number 
aberrations [%] iFISH 
routine 
MLPA iFISH 
confirmatory for 
MLPA 
49 del(13)(q14.3q14.3)[83] + + o 
50 del(13)(q14.3q14.3)[85] + + o 
51 del(13)(q14.3q14.3)[91] + + o 
52 del(13)(q14.3q14.3)[94] + + o 
53 del(13)(q14.3q14.3)[94.5] + + o 
54 del(11)(q22.3q22.3)[98] 
del(13)(q14.2q14.2)[41] 
del(13)(q14.2q14.2)x2[39] 
del(13)(q14.3q14.3)[97] 
+ 
o 
o 
+ 
+ 
+ 
(+) 
+ 
o 
+ 
+ 
o 
55 del(13)(q14.2q14.2)[73] 
del(13)(q14.2q14.2)x2[5] 
del(13)(q14.3q14.3)[85] 
o 
o 
+ 
+ 
(+) 
+ 
+ 
+ 
o 
56 del(13)(q14.2q14.2)[22] 
del(13)(q14.2q14.2)x2[58] 
del(13)(q14.3q14.3)[12] 
del(13)(q14.3q14.3)x2[66] 
o 
o 
+ 
+ 
+ 
(+) 
+ 
(+) 
+ 
+ 
o 
o 
57 der(1)t(1;4)(q1?2;q?31)[90] 
der(4)t(4;?10)(q?31;q24)[90] 
?der(10)t(10;16)(q24;p?11.2)[90] 
der(15)t(1;15)(q1?2;q1?2)[90] 
der(16)t(15;16)(q1?2;p?11.2)[90] 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
58 der(2)t(2;13)(q?37;q?14)[21] 
?del(6)(p?23)[21] 
del(11)(q22.3q22.3)[87] 
del(13)(q14.3q14.3)[87] 
del(14)(q32q32)[85] 
o 
o 
+ 
+ 
+ 
o 
o 
+ 
+ 
o 
o 
o 
o 
o 
o 
59 del(14)(q32q32)[85]  + o o 
60 rea(14)(q32.33)[96] -> t(14;?)(q32;?) + o o 
61 t(3;?)(q2?9;?)[22] 
-7[22] 
+12[78] 
del(14)(q32q32)[94]  
del(17)(p13.1p13.1)[95] 
amp(17)(q25.1q25.2)[22] 
o 
o 
+ 
+ 
+ 
o 
o 
o 
+ 
o 
+ 
+ 
o 
o 
o 
o 
o 
+ 
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Supplementary Table 2 (Article 2 - continued)  
sample 
number 
aberrations [%] iFISH 
routine 
MLPA iFISH 
confirmatory for 
MLPA 
62 +12[80] 
del(13)(q14.3q14.3)[62] 
amp(18)(p11.21q11.21)[75] 
amp(18)(q21.2q21.2)[75] 
+ 
+ 
o 
o 
+ 
+ 
+ 
+ 
o 
o 
+ 
+ 
63 amp(2)(p24.3p24.3)[62.5] 
amp(2)(p23.2~23.1p23.2~23.1)[62.5] 
del(11)(q22.3q22.3)[95] 
del(13)(q14.2q14.2)[51] 
del(13)(q14.2q14.2)x2[38] 
del(13)(q14.3q14.3)[90] 
del(14)(q32q32)[91] 
o 
o 
+ 
o 
o 
+ 
+ 
+ 
+ 
+ 
+ 
(+) 
+ 
o 
+ 
+ 
o 
+ 
+ 
o 
o 
64 amp(2)(p24.3p24.3)[65] 
amp(2)(p23.2~23.1p23.2~23.1)[75] 
del(11)(q22.3q22.3)[83] 
del(13)(q14.3q14.3)[58.5] 
o 
o 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
o 
o 
65 amp(6)(q27q27)[?] 
del(11)(q22.3q22.3)[93] 
del(13)(q14.3q14.3)[96] 
o 
+ 
+ 
+ 
+ 
+ 
- 
o 
o 
66 del(13)(q14.3q14.3)[90] 
del(14)(q32q32)[81] 
amp(18)(q21.2q21.2)[?] 
+ 
+ 
o 
+ 
o 
+ 
o 
o 
- 
67 del(13)(q14.3q14.3)[60] 
del(14)(q32q32)[80] 
amp(18)(p11.21q11.21)[?] 
+ 
+ 
o 
+ 
o 
+ 
o 
o 
- 
68 del(6)(q21q21)[33] 
del(6)(q23.3q23.3)[92] 
o 
o 
+ 
+ 
+ 
+ 
69 amp(21)(q22.12q22.12)[50] o + + 
70 ?add(1q)(q4)[50] o o o 
71 None n n o 
72 None n n o 
73 None n n o 
74 none n n o 
75 none n n o 
76 none n n o 
77 none n n o 
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Supplementary Table 2 (Article 2 - continued)  
sample 
number 
aberrations [%] iFISH 
routine 
MLPA iFISH 
confirmatory for 
MLPA 
78 none n n o 
79 none n n o 
80 None n n o 
81 none n n o 
82 none n n o 
83 none n n o 
84 none n n o 
85 none n n o 
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